EP4704957A1 - Polymeric structures having polymeric microneedles and methods for making and using same - Google Patents

Abstract

Aspects of the present disclosure include polymeric structures having one or more polymeric microneedles. Polymeric structures according to certain embodiments include a microstructural component configured to facilitate one or more of insertion of the polymeric microneedle into a skin surface of a subject; retention of the polymeric microneedle in the skin of the subject; creating a seal when the polymeric microneedle is inserted into the skin of the subject; and delivery of an active agent to a subject through the polymeric microneedle. Methods for applying a polymeric structure having polymeric microneedles to a skin surface of a subject is also described. Methods for making the polymeric structures, such as by high resolution continuous liquid interface production are also provided. Kits having one or more of the subject polymeric structures are also described.

Description

Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 POLYMERIC STRUCTURES HAVING POLYMERIC MICRONEEDLES AND METHODS FOR MAKING AND USING SAME CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63/538,369, filed on September 14, 2023, and U.S. Provisional Patent Application No. 63/462,685, filed on April 28, 2023, which applications are incorporated herein by reference in their entireties. GOVERNMENT RIGHTS This invention was made with Government support under contract T32 CA009695 (TRAINING GRANT) awarded by the National Institutes of Health. The Government has certain rights in the invention. INTRODUCTION The intradermal (ID) space has been actively explored as a means for drug delivery and diagnostics that are minimally invasive. Intradermal drug delivery is the process of delivering formulations into layers of skin. ID access necessitates puncturing the outermost layer of skin called the stratum corneum (StC), a tough barrier that provides mechanical integrity for the skin. Human skin is a complex, multi-layer organ, that includes the stratum corneum, epidermis, dermis and hypodermis. Often, these treatments target either the epidermal or dermal layers of skin, which are situated above blood vessels and nerve fibers of the skin. It offers an attractive alternative to intravenous (IV) injection, which often elicits systemic effects and can be particularly advantageous for targeted, local drug delivery. ID drug delivery can provide for the ability to deliver compounds with a significant first-pass effect, or metabolization by the liver which can prematurely degrade the therapeutic compound, upon systemic administration. Further, ID access also reduces pain associated with hypodermic injections and can help eliminate the risk of transmitting blood-borne diseases through the generation of dangerous medical waste. ID access can also be self-administered and can eliminate reliance on trained medical professionals. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 Microneedles or microneedle patches or Micro-Array Patches (MAPs) have a series of micrometer-sized projections that can painlessly puncture the skin and access the epidermal/dermal layer and facilitate sampling of interstitial fluid. MAPs are employed in cosmetics, such as for use in treating acne scars and stretch marks by penetrating the stratum corneum to create micro conduits that stimulate growth factor secretion and collagen production. Microneedles are conventionally solid or hollow microneedles that are micro-molded from templates and fabricated by a three-step process master fabrication, mold fabrication and mold filling to generate hollow, metallic projections with uniform geometries. Microneedles have been generally manufactured to be produced in a manner like conventional hypodermic needles. SUMMARY Aspects of the present disclosure include polymeric structures having one or more polymeric microneedles. Polymeric structures according to certain embodiments include a microstructural component configured to facilitate one or more of insertion of the polymeric microneedle into a skin surface of a subject; retention of the polymeric microneedle in the skin of the subject; creating a seal when the polymeric microneedle is inserted into the skin of the subject; and delivery of an active agent to a subject through the polymeric microneedle. Methods for applying a polymeric structure having polymeric microneedles to a skin surface of a subject is also described. Methods for making the polymeric structures, such as by high resolution continuous liquid interface production are also provided. Kits having one or more of the subject polymeric structures are also described. In embodiments, each polymeric microneedle includes a tip section, a body section and a base section. In some instances, one or more of the polymeric microneedles includes a body section having a width that is greater than the width of the base section. In some instances, the width of the body section is 25% greater or more than the width of the base section. In some instances, the base section of each polymeric microneedle has a circular cross-section. In some instances, one or more of the polymeric microneedles is tear-drop shaped. In some instances, one or more of the polymeric microneedles comprises a base section having a width that varies along a longitudinal axis of the base section. In some instances, the base section includes a first Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 end having a first width, a second end having a second width and a middle section between the first end and the second end having a third width. In some instances, the middle section has a width which is less than width of the first end and the width of the second end. In some instances, the first width, the second width and the third width are different from each other. In some instances, the first width is from 25 µm to 500 µm. In some instances, the second width is from 25 µm to 500 µm. In some instances, the third width is from 1 µm to 100 µm. In certain instances, one or more of the polymeric microneedles has an arrowhead shape. In certain instances, one or more of the polymeric microneedles comprises a square pyramidal or conical projection shape. In some embodiments, one or more of the polymeric microneedles has a lattice microstructure. In some instances, the lattice microstructure has a plurality of struts. In some instances, one or more of the polymeric microneedles comprises a gradient in the number of struts such that the density of struts increases across a longitudinal axis of the microneedle. In some instances, the struts have a thickness of from 25 µm to 150 µm. In some instances, one or more of the polymeric microneedles has a gradient in the thickness of the struts such that the thickness of the struts increases across a longitudinal axis of the microneedle. In some instances, the thickness of the struts increases from the tip section to the base section of the polymeric microneedle. In some instances, one or more of the polymeric microneedles further has a pillar in contact with the base section of the polymeric microneedle. In some instances, the pillar has a solid structure. In some instances, the pillar has a lattice microstructure. In some instances, each of the tip section, the body section and the base section has the same cross-sectional shape. In some instances, one or more of the tip section, the body section and the base section has a different cross-sectional shape. In some instances, one or more of the tip section, the body section and the base section has a rigid cross cross-sectional shape. In some instances, each of the tip section, the body section and the base section has a rigid cross cross-sectional shape. In some instances, the body section and the base section has a rigid cross cross-sectional shape. In certain instances, the tip section has a conical cross-sectional shape. In some instances, one or more of the polymeric microneedles has a beveled tip section. In some embodiments, the tip section of the polymeric microneedle includes a bevel angle of from 3° to 45°. In some embodiments, one or more of the polymeric Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 microneedles is positioned at an angle of 5° to 60°, such as with respect to the skin surface of the subject. In some instances, one or more of the polymeric microneedles has a hollow internal space. In some instances, one or more of the polymeric microneedles has a tip section having a solid structure, a body section having a hollow structure and a base section having a solid structure. In some instances, wherein one or more of the polymeric microneedles has a tip section having a solid structure, a body section having a lattice structure and a base section having a solid structure. In some instances, one or more of the polymeric microneedles has a tip section having a lattice structure, a body section having a hollow structure and a base section having a solid structure. In some embodiments, one or more of the polymeric microneedles has a solid tip section and a body section and a base section that comprises one or more microfluidic channels. In some instances, the body section has an outlet for one of more of the microfluidic channels. In certain instances, there is no outlet for the microfluidic channel at the tip section of the polymeric microneedle. In some instances, the tip section includes an outlet for one or more of the microfluidic channels. In some instances, one or more of the tip section, the body section and the base section has a hollow internal space. In some instances, one or more of the polymeric microneedles has a tip section having a solid structure, a body section having a hollow structure and a base section having a solid structure. In some embodiments, one or more of the polymeric microneedles are fenestrated. In some instances, one or more of the tip section, the body section and the base section are fenestrated. In some instances, the tip section is fenestrated. In some instances, the body section is fenestrated. In some embodiments, one or more of the polymeric microneedles has a stinger- type shape. In some instances, one or more of the polymeric microneedles has a bee- stinger shape. In some instances, one or more of the polymeric microneedles has a scorpion-stinger shape. In some embodiments, one or more of the polymeric microneedles has a fang-type shape. In some instances, one or more of the polymeric microneedles has a snake-fang (e.g., viper) shape. In certain instances, one or more of the polymeric microneedles has a spider-fang shape. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 In some instances, each polymeric microneedle has a tip section that has a length of from 25 µm to 500 µm. In some instances, the tip section has a base width of 50 µm to 300 µm. In some instances, each polymeric microneedle has a tip diameter of from 0.1 µm to 10 µm. In some instances, each polymeric microneedle has a body section that has a length of from 50 µm to 1000 µm. In some instances, the body section has a width of 50 µm to 300 µm. In some instances, each polymeric microneedle has a base section that has a length of from 25 µm to 500 µm. In some instances, the base section has a base width of 50 µm to 300 µm. In some instances, each polymeric microneedle has a volume of from 0.01 µL to 2 µL. In some instances, the polymeric structure is formed from one or more polymerizable materials. In some instances, the polymeric structure is formed from two or more different polymerizable materials. In some instances, each polymerizable material is selected from polycaprolactone, polyglycolic acid, polylactic acid, polylactic- co-glycolic acid, polyethylene glycol, polyethylene glycol dimethacrylate (PEGDMA), thiol-enes, anhydrides, polyacrylic acid, poly methylmethacrylate, trimethylolpropane triacrylate (TMPTA) monomer, polyvinyl alcohol, polyvinylpyrrolidone, vinyl carbonates, vinyl esters, acrylamides, hyaluronic acid, chitosan, collagen, gelatin, carboxymethylcellulose, and blends or copolymers thereof. In some instances, the polymerizable material includes carbon nanotubes. In some instances, one or more of the polymeric microneedles is formed from a biodegradable polymerizable material. In some instances, the polymeric microneedles are dissolvable in an aqueous medium. In some embodiments, one or more of the polymeric microneedles further includes an active agent compound. In some instances, the active agent is a small molecule active agent compound. In some instances, the active agent is an immunogenic active agent compound. In some instances, the active agent compound is a vaccine. In some instances, the active agent compound is lyophilized. In some instances, one or more of the polymeric microneedles includes a hydrogel which incorporates the active agent compound. In certain instances, the active agent compound is an unreconstituted solid. In some embodiments, the polymeric structure is in fluid communication with one or more microfluidic channels. In some instances, the polymeric structure includes a plurality of microfluidic channels. In some instances, the microfluidic channels are in Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 fluid communication with a source of a fluidic medium. In some instances, the microfluidic channels are in fluid communication with a reservoir. In some instances, the polymeric structure is in fluidic communication with a pump component. In some instances, the polymeric structure is configured to convey a fluidic medium from the microfluidic channels through the polymeric microneedles. In some instances, the polymeric structure is configured to draw a fluidic medium through the polymeric microneedles into the microfluidic channels. In some instances, the microfluidic channels comprise a geometric shape configured to control the conveyance rate of a fluidic medium therein. In some instances, the polymeric structure includes a plurality of polymeric microneedles. In some instances, the polymeric structure includes an array of polymeric microneedles. In some instances, the polymeric structure further includes a connector configured to couple the polymeric structure to a fluid reservoir. In some instances, the connector includes a Luer-lock fitting. In some embodiments, one or more polymeric microneedles are in fluid communication with a reservoir. In some instances, the reservoir is part of a backing structure for the polymeric structure. In some instances, the reservoir is an integrated component of the polymeric structure. In some instances, each polymeric microneedle is in fluidic communication with a distinct reservoir. In some instances, the distinct reservoirs are in fluid communication with each other through one or more microchannels positioned in the backing structure. In some instances, the polymeric microneedle is in fluidic communication with the one or more reservoirs through a microfluidic channel which outlets from a body section or base section of the polymeric microneedle (e.g., to deliver an active agent to a subject or to collect a biological sample from the subject). Aspects of the present disclosure also include methods for applying the polymeric structures having a plurality of polymeric microneedles to a skin surface of a subject. In some instances, the polymeric structure includes microneedles arranged in an array on a substrate. In some instances, the polymeric structure has a backing structure which includes one or more reservoirs in fluidic communication with the polymeric microneedles. In some instances, each of the polymeric microneedles is in fluidic communication with a different reservoir of the backing structure. In some instances, the polymeric structure further includes a backing layer (e.g., having a Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 pressure sensitive adhesive). In certain instances, the polymeric structure is applied to the skin surface of the subject and maintained in contact with the subject for an extended period of time, such as for 30 minutes or longer, such as 1 hour or longer and including for 6 hours or longer. In certain instances, the patch is applied to the skin surface of the subject and removed within 15 minutes or less, such as within 5 minutes or less and including within 1 minute or less. In some embodiments, methods include applying the polymeric structure to deliver a therapeutically effective amount of an active agent compound to the subject. In these embodiments, the plurality of polymeric microneedles contain an active agent compound and the polymeric structure is maintained in contact with the subject for a period of time sufficient to deliver one or more doses of the active agent compounds, such 2 or more doses and include 5 or more doses. In certain cases, some instances, the polymeric structure is maintained in contact with the subject for sustained release of the active agent to the subject over a period of time. In some instances, methods include applying the polymeric structure to the skin surface of the subject in a manner sufficient to collect a biological fluid sample from the subject into the microneedles. In some embodiments, methods include collecting interstitial fluid from the subject into the microneedles. In other embodiments, methods include collecting dermal fluid from the subject into the microneedles. Methods according to certain instances, include collecting 0.01 µL to 250 µL of the biological fluid from the subject, such as from 0.01 µL to 2 µL. In some embodiments, methods include collecting a biological fluid sample from the subject (e.g., interstitial fluid, dermal fluid) for detecting an analyte present in the biological sample, such as for detecting glucose. Aspects of the disclosure also include methods for making a polymeric structure having one or more polymeric microneedles as described above. Methods according to certain embodiments, include irradiating a polymerizable composition positioned between a build elevator and a build surface to generate a polymerizable composition having a first polymerized region of the polymerizable composition in contact with the build elevator and a first non-polymerized region of the polymerizable composition in contact with the build surface; displacing the build elevator away from the build surface; irradiating the first non-polymerized region of the polymerizable composition to generate a second polymerized region of the polymerizable composition in contact with the first Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 polymerized region and a second non-polymerized region in contact with the build surface and repeating in a manner sufficient to generate the polymeric structure. In some embodiments, the polymerizable composition is in contact with the build elevator and the build surface. In some instances, methods include irradiating the polymerizable composition for a duration sufficient to bond the first polymerized region of the polymerizable composition to the build elevator. In some instances, the build elevator is displaced in predetermined increments of from 0.5 µm to 1.0 µm. In certain instances, polymerizable composition is added to the build surface after each displacement of the build elevator away from the build surface. In some embodiments, the polymerizable composition is irradiated through build surface. In some instances, the polymerizable composition is irradiated in the presence of a polymerization inhibitor. In certain embodiments, the polymerizable composition is continuously polymerized while displacing the build elevator away from the build surface. In certain cases, the polymerization inhibitor is oxygen and the build surface is permeable to oxygen. In some embodiments, methods include preparing a polymeric structure having polymeric microneedles that include an active agent compound. In some instances, the active agent compound is coated onto a surface of the polymeric microneedles. In some embodiments, the active agent compound is coated onto the surface of the polymeric microneedle by dip-coating or by spray coating. In other instances, the active agent compound is dry-cast (e.g., as a powder) onto the surface of the polymeric microneedles. In some instances, the active agent compound is incorporated into an interior space of the polymeric microneedles. In some instances, the active agent is injected into the interior space of the polymeric microneedles (e.g., the lattice microstructure). In other instances, the active agent is introduced into the polymeric microneedle by contacting the lattice microstructure with a composition containing the active agent compound and incorporating the active agent by capillary action. In yet other instances, the active agent compound is incorporated into the polymerizable composition and is incorporated within the interior space of the polymeric microneedle while forming the lattice microstructure. In some instances, methods include incorporating a lyophilized active agent compound into the interior space of one or more of the polymeric microneedles. In certain instances, methods include lyophilizing in-situ the active agent-containing composition in the polymeric microneedle. In certain Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 instances, methods include generating a hydrogel from the active agent composition and incorporating the hydrogel into the interior space of one or more of the polymeric microneedles. In certain instances, methods include generating the hydrogel in-situ in the interior space of the polymeric microneedle (e.g., in-situ polymerization) BRIEF DESCRIPTION OF THE FIGURES The invention may be best understood from the following detailed description when read in conjunction with the accompanying drawings. Included in the drawings are the following figures: FIG.1A depicts polymeric structures having an array of polymeric microneedles according to certain embodiments. FIGS.1B and 1C depict an example of the effect of spacing distance between microneedles when pressed through a plurality of membrane layers according to certain embodiments. FIG.2 depicts polymeric structures having an array of different microneedle heights according to certain embodiments. FIG.3 depicts a flexible polymeric structure where the array of polymeric microneedles are positioned in a rolling arrangement according to certain embodiments. FIG.4A depicts the variation of different three-dimensional geometric shaped components of polymeric microneedles according to certain embodiments. FIG.4B depicts examples of polymeric microneedles having different cross-sectional shapes and geometric configurations for different sections (e.g., tip, body, base) of the polymeric microneedle according to certain embodiments. FIG.5A depicts polymeric microneedles having different cross-shaped cross- sections according to certain embodiments. FIG.5B depicts an example of the effect of cross-section shape of the polymeric microneedles when pressed through a plurality of membrane layers according to certain embodiments. FIG.6A depicts polymeric microneedles having different length tip sections having a conical cross-sectional shape according to certain embodiments. FIG.6B depicts an example of the effect of different length conical tip polymeric microneedles when pressed through a plurality of membrane layers according to certain embodiments. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 FIG.7 depicts examples of biologically-mimicked shaped designs of polymeric microneedles according to certain embodiments. FIG.8 depicts polymeric microneedles having a solid tip section and body and base sections which include a microfluidic channel position therethrough according to certain embodiments. FIG.9 depicts examples of teardrop shaped polymeric microneedles according to certain embodiments. FIG.10 depicts examples of tapered shaped polymeric microneedles according to certain embodiments. FIG.11A depicts examples of pillared shaped polymeric microneedles according to certain embodiments. FIG.11B depicts a schematic of the retention of cargo delivery in the skin when administered with pillared shaped polymeric microneedles according to certain embodiments. FIG.12 depicts an example of an arrowhead-shaped polymeric microneedle according to certain embodiments. FIG.13 depicts examples of bevel-shaped polymeric microneedles according to certain embodiments. FIG.14 depicts examples of fenestrated polymeric microneedles according to certain embodiments. FIG.15A a polymeric structure having a fluidic reservoir in fluid communication with polymeric microneedles according to certain embodiments. FIG.15B depicts coupling the polymeric structure with a reservoir through a connector (e.g., a Luer lock connection) according to certain embodiments. FIG.16 depicts a microfluidic distribution system for integrating/connecting to a polymeric microstructure having a plurality of microneedles according to certain embodiments. FIG.17 depicts an active injection pump system for conveying a composition in microfluidic channels through microneedles of a polymeric structure according to certain embodiments. FIG.18 depicts microfluidic channel configurations for controlling flow rate according to certain embodiments. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 FIG.19 depicts the delivering a mixed compositions through polymeric microneedles using a microfluidic channel network according to certain embodiments. FIG.20 depicts in situ synthesis using microfluidic channels in fluid communication with a microneedle of a polymeric structure according to certain embodiments. FIG.21 depicts an example of delivering a plurality of different compositions (e.g., different active agents) through an array of microneedles according to certain embodiments. FIG.22 depicts polymeric microneedles having an incorporated lyophilized composition according to certain embodiments. FIG.23 depicts liquid injection reconstitution of a lyophilized composition with a polymeric structure and microfluidic channel network according to certain embodiments. FIG.24 depicts using pressure fields in a polymeric structure and microfluidic channel network to reconstitute a lyophilized composition according to certain embodiments. FIG.25 depicts using a hydrogel to reconstitute a lyophilized composition in polymeric microneedles according to certain embodiments. FIG.26 depicts active extraction of interstitial fluid through microneedles and a microfluidic channel network according to certain embodiments. FIG.27 depicts the use of electrodes within a microfluidic network to generate electrohydrodynamic extraction of biological fluid through microneedles of a polymeric structure according to certain embodiments. DETAILED DESCRIPTION Aspects of the present disclosure include polymeric structures having one or more polymeric microneedles. Polymeric structures according to certain embodiments include a microstructural component configured to facilitate one or more of insertion of the polymeric microneedle into a skin surface of a subject; retention of the polymeric microneedle in the skin of the subject; creating a seal when the polymeric microneedle is inserted into the skin of the subject; and delivery of an active agent to a subject through the polymeric microneedle. Methods for applying a polymeric structure having polymeric microneedles to a skin surface of a subject is also described. Methods for making the Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 polymeric structures, such as by high resolution continuous liquid interface production are also provided. Kits having one or more of the subject polymeric structures are also described. Before the present invention is described in greater detail, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims. Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention. Certain ranges are presented herein with numerical values being preceded by the term "about." The term "about" is used herein to provide literal support for the exact number that it precedes, as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximating unrecited number may be a number which, in the context in which it is presented, provides the substantial equivalent of the specifically recited number. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative illustrative methods and materials are now described. All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed. It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible. While the apparatus and method has or will be described for the sake of grammatical fluidity with functional explanations, it is to be expressly understood that the claims, unless expressly formulated under 35 U.S.C. §112, are not to be construed as necessarily limited in any way by the construction of "means" or "steps" limitations, but are to be accorded the full scope of the meaning and equivalents of the definition provided by the claims under the judicial doctrine of equivalents, and in the case where the claims are expressly formulated under 35 U.S.C. §112 are to be accorded full statutory equivalents under 35 U.S.C. §112. P^OLYMERIC S^{TRUCTURES HAVING} P^OLYMERIC M^ICRONEEDLES Aspects of the present disclosure include polymeric structures having one or more polymeric microneedles configured to facilitate one or more of insertion of the polymeric microneedle into a skin surface of a subject, retention of the polymeric microneedle in the skin of the subject, creating a seal when the polymeric microneedle is Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 inserted into the skin of the subject and delivery of an active agent to a subject through the polymeric microneedle. In embodiments, polymeric structures include one or more polymeric microneedles. In some instances, the polymeric structure includes a plurality of microneedles, such as 2 or more polymeric microneedles, such as 3 or more, such as 4 or more, such as 5 or more, such as 10 or more, such as 25 or more, such as 50 or more, such as 100 or more, such as 250 or more, such as 500 or more and including 1000 polymeric microneedles or more. In some instances, the polymeric structure includes an array of polymeric microneedles. In some instances, the polymeric microneedles or the array are arranged in one or more lines. For example, the polymeric microneedles may be positioned along 2 or more parallel lines, such as 3 or more, such as 4 or more, such as 5 or more, such as 6 or more, such as 7 or more, such as 8 or more, such as 9 or more, such as 10 or more, such as 15 or more, such as 20 or more and including 25 or more parallel lines of microneedles. In certain instances, the polymeric microneedles are arranged into a geometric configuration, where arrangements of interest include, but are not limited to a square configuration, rectangular configuration, trapezoidal configuration, triangular configuration, hexagonal configuration, heptagonal configuration, octagonal configuration, nonagonal configuration, decagonal configuration, dodecagonal configuration, circular configuration, oval configuration as well as irregular shaped configurations. In certain instances, the polymeric microneedles are arranged in a random configuration. In some embodiments, the microneedles are separated from each other on the polymeric structure by an average distance of from 1 µm to 1000 µm, such as from 2 µm to 950 µm, such as from 3 µm to 900 µm, such as from 4 µm to 850 µm, such as from 5 µm to 800 µm, such as from 6 µm to 750 µm, such as from 7 µm to 700 µm, such as from 8 µm to 650 µm, such as from 9 µm to 600 µm, such as from 10 µm to 550 µm, such as from 15 µm to 500 µm, such as from 20 µm to 450 µm and including from 25 µm to 400 µm. The plurality of polymeric microneedles may each be the same size or patches may include plurality of polymeric microneedles having different sizes. Each polymeric microneedle independently may have a length of from 50 µm to 2000 µm, such as from 75 µm to 1950 µm, such as from 100 µm to 1900 µm, such as from 125 µm to 1850 µm, such as from 150 µm to 1800 µm, such as from 175 µm to 1750 µm, such Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 as from 200 µm to 1700 µm, such as from 225 µm to 1650 µm, such as from 250 µm to 1600 µm, such as from 275 µm to 1550 µm and including from 300 µm to 1500 µm. Each polymeric microneedle independently may have a width (diameter when the polymeric microneedle has a circular cross-section) of from 50 µm to 1000 µm, such as from 75 µm to 950 µm, such as from 100 µm to 900 µm, such as from 125 µm to 850 µm, such as from 150 µm to 800 µm, such as from 175 µm to 750 µm, such as from 200 µm to 700 µm, such as from 225 µm to 650 µm, such as from 250 µm to 600 µm, such as from 275 µm to 550 µm and including from 300 µm to 500 µm. In some embodiments, the polymeric microneedles are angled, such as with respect to the polymeric structure, such as at an angle of 5° to 60°, such as from 10° to 55°, such as from 15° to 50°, such as from 20° to 45° and including being slanted from 25° to 40° with respect to the polymeric structure. In some embodiments, the polymeric microneedles are angled with respect to the skin surface of a subject, such as at an angle of 5° to 60°, such as from 10° to 55°, such as from 15° to 50°, such as from 20° to 45° and including being slanted from 25° to 40° with respect to the skin surface of a subject. Figure 1A depicts polymeric structures having an array of polymeric microneedles according to certain embodiments. As shown in Figure 1A, the polymeric microneedles may be arranged in parallel rows, each row having the same or different number of polymeric microneedles. Spacing between the polymeric microneedles may vary depending on the desired density of microneedles as well as size and length of the microneedles. As shown in Figure 1A, in some instances, the polymeric microneedles may be arranged at different angles and alignment with respect to each other. (Figure 1A, right array showing unparallel alignment between the polymeric microneedles on the polymeric structure). Figures 1B and 1C depict an example of the effect of spacing distance between different microneedles when pressed through 5 layers of a parafilm (each layer being about 0.6mm thick) with different types of microneedles. In Figures 1B and 1C, microneedles separated by 1.5 mm, 2.0 mm and 2.5 mm were pressed through 5 layers and the effect on each layer was recorded. In certain instances, the polymeric structure includes an array of polymeric microneedles where the array includes polymeric microneedles having different lengths. In some instances, the polymeric microneedles are arranged on the polymeric structure Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 to have random lengths throughout the array. In certain instances, the different lengths of polymeric microneedles have a predetermined arrangement in the array, such as where longer polymeric microneedles are positioned along an outside edge of the array and shorter polymeric microneedles are positioned along the inside of the array. In other instances, the longer polymeric microneedles are positioned on the inside of the array and the shorter polymeric microneedles are positioned along an outside edge of the array. In some instances, the longer polymeric microneedles are positioned on one side of the polymeric structure and the shorter polymeric microneedles are positioned on another side of the polymeric structure. In some instances, the polymeric structure includes a plurality of rows of polymeric microneedles and one or more of the rows include longer polymeric microneedles and one or more of the rows include shorter polymeric microneedles. In some instances, the rows with longer polymeric microneedles alternate with the rows with the shorter polymeric microneedles. Figure 2 depicts polymeric structures having an array of different microneedle heights according to certain embodiments. As shown in Figure 2, in some instances polymeric microneedles having a greater length are grouped together in one section of the array. In other instances, the different length polymeric microneedles may be positioned in a configuration where the polymeric microneedles alternate in length (e.g., short, long, short, long). In some embodiments, the polymeric structure is flexible. The term flexible is used herein in its conventional sense to refer to the elasticity and non-permanent deformation of the polymeric structure. In some instances, the polymeric structure has a Young’s modulus which ranges from 0.01 GPa to 500 GPa, such as from 0.05 GPa to 400 GPa, such as from 0.1 GPa to 300 GPa, such as from 0.5 GPa to 200 GPa, such as from 1 GPa to 100 GPa and including from 10 GPa to 50 GPa. In some instances, the polymeric structure exhibits a durometer hardness of 100 or less, such as 90 or less, such as 80 or less, such as 70 or less, such as 60 or less, such as 50 or less and including a durometer hardness of 40 or less. In certain instances, the polymeric structure is flexible and the array of polymeric microneedles utilizes a rolling arrangement such as where the rows of polymeric microneedles exhibit tips at different radial positions along the rolling arrangement. Figure 3 depicts a flexible polymeric structure where the array of polymeric microneedles Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 are positioned in a rolling arrangement according to certain embodiments. As shown in Figure 3, the tips of the polymeric microneedles are positioned across different radial positions along the rolling arrangement. In certain instances, the flexible polymeric structure provides for positioning one or more rows of polymeric microneedles at different angles. In some instances, a flexible polymeric structure includes a plurality of rows of polymeric microneedles and one or more rows are positioned at a different angle, such as 2 or more rows, such as 3 or more rows and including 4 or more rows. Each of the rows may be positioned such that the polymeric microneedles have the same or different angles. Where the angles are different, each row may differ in the position angle of the row of polymeric microneedles by 1° or more, such as by 2° or more, such as by 3° or more, such as by 4° or more, such as by 5° or more, such as by 10° or more, such as by 15° or more, such as by 20° or more, such as by 25° or more, such as by 30° or more, such as by 45° or more and including by 60° or more. In certain instances, one or more rows of polymeric microneedles are positioned at a 90° angle with respect to the other rows of the polymeric microneedles on the polymeric structure. In some embodiments, polymeric microneedles described herein have a lattice microstructure. In some instances, the lattice microstructures of the polymeric microneedles described herein have 2 or more repeating lattice cell units, such as 3 or more repeating lattice cell units, such as 4 or more repeating lattice cell units and including 5 or more repeating lattice cell units. In some instances, the lattice microstructure has a lattice shape selected from tetrahedral, Kagome, rhombic, icosahedral, Voronoi or triangular. In some instances, the lattice microstructure is composed of two or more lattice cell units having different lattice shapes, such where the lattice microstructure is composed of 3 or more different lattice shapes, such as 4 or more different lattice shapes and including where the lattice microstructure is composed of 5 or more different lattice shapes. In some embodiments, the lattice microstructure is formed from lattice cells having a unit size of from 1 µm to 1000 µm, such as from 5 µm to 950 µm, such as from 10 µm to 900 µm, such as from 15 µm to 850 µm, such as from 20 µm to 800 µm, such as from 25 µm to 750 µm, such as from 30 µm to 700 µm, such as from 35 µm to 650 µm, such as from 40 µm to 600 µm, such as from 45 µm to 550 µm and including from 50 µm to 500 µm, for example from 200 µm to 500 µm. In embodiments, the lattice Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 microstructure has a volume of from 0.01 µL to 25 µL, such as from 0.02 µL to 24.5 µL, such as from 0.03 µL to 24 µL, such as from 0.04 µL to 23.5 µL, such as rom 0.05 µL to 23 µL, such as from 0.6 µL to 22.5 µL, such as from 0.07 µL to 22 µL, such as from 0.08 µL to 21.5 µL, such as from 0.09 µL to 21 µL, such as from 0.1 µL to 20 µL, such as from 0.5 µL to 19 µL, such as from 1 µL to 18 µL, such as from 2 µL to 17 µL, such as from 3 µL to 16 µL and including from 4 µL to 15 µL. As described in greater detail below, the polymeric structure may be configured to contain a composition within the lattice microstructure (e.g., a fluidic composition) where in some embodiments the lattice microstructure is configured to contain a volume of from 0.1 µL to 25 µL, such as from 0.2 µL to 24 µL, such as from 0.3 µL to 23 µL, such as from 0.4 µL to 22 µL, such as rom 0.5 µL to 21 µL, such as from 0.6 µL to 20 µL, such as from 0.7 µL to 19 µL, such as from 0.8 µL to 18 µL, such as from 0.9 µL to 17 µL and including where the lattice microstructure is configured to contain a volume of from 1 µL to 15 µL. In some embodiments, the density of lattice cell units remains constant throughout the lattice microstructure of polymeric structures of interest. In some instances, lattice microstructures have different densities of lattice cell units. In some instances, polymeric microneedles have a low density of lattice cell units, a medium density of lattice cell units and a high density of lattice cell units. In other embodiments, the density of lattice cell units varies at one or more parts of the lattice microstructure. In some embodiments, the lattice microstructure contains regions of increased lattice cell density, such as where the lattice cell density in these regions is increased by 1% or more across the longitudinal axis of the lattice microstructure, such as by 2% or more, such as by 3% or more, such as by 4% or more, such as by 5% or more, such as by 10% or more, such as by 20% or more, such as by 30% or more, such as by 40% or more and including by 50% or more. In some instances, the regions of increased lattice cell density are present at various increments across the longitudinal axis of the lattice microstructure. For example, the regions of increased lattice cell density may be present at increments of every 10 µm or more across the longitudinal axis of the lattice microstructure, such as every 20 µm or more, such as every 30 µm or more, such as every 40 µm or more and including every 50 µm or more. In some instances, lattice microstructures have a gradient in the density of lattice cell units according to certain embodiments. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 In some instances, the density of lattice cell units exhibits a gradient in one or more parts of the lattice microstructure. In certain instances, the density of lattice cell units gradually increases across a longitudinal axis of the lattice microstructure. For example, the density of the lattice cell units may increase by 1% or more across the longitudinal axis of the lattice microstructure, such as by 2% or more, such as by 3% or more, such as by 4% or more, such as by 5% or more, such as by 10% or more, such as by 20% or more, such as by 30% or more, such as by 40% or more and including by 50% or more. In some embodiments, the density of the lattice cell units increases at predetermined increments across the longitudinal axis of the lattice microstructure, such as where the density of the lattice cell units increases every 1% or more of the length across the longitudinal axis of the lattice microstructure, such as every 2% or more, such as every 3% or more, such as every 4% or more, such as every 5% or more, such as every 6% or more, such as every 7% or more, such as every 8% or more, such as every 9% or more and including every 10% or more. Depending on the size of the lattice microstructure, the density of the lattice cell units may increase every 1 µm or more across the longitudinal axis, such as every 2 µm or more, such as every 3 µm or more, such as every 4 µm or more, such as every 5 µm or more, such as every 10 µm or more, such as every 20 µm or more, such as every 30 µm or more, such as every 40 µm or more and including every 50 µm or more. For example, the density of the lattice cell units may increase by 1% or more every 25 µm or more across the longitudinal axis of the lattice microstructure, such as by 2% or more every 25 µm or more across the longitudinal axis of the lattice microstructure, such as 5% or more every 25 µm or more across the longitudinal axis of the lattice microstructure. In some embodiments, the lattice microstructure includes a plurality of struts. Struts according to certain embodiments provide mechanical integrity to the lattice microstructure. In some instances, struts have a thickness which range from 1 µm to 200 µm, such as from 2 µm to 190 µm, such as from 3 µm to 180 µm, such as from 4 µm to 170 µm, such as from 5 µm to 160 µm, such as from 6 µm to 150 µm, such as from 7 µm to 140 µm, such as from 8 µm to 130 µm, such as from 9 µm to 120 µm and including from 10 µm to 100 µm. For instance, the strut size may be in certain examples from 50 µm to 100 µm such as 70 µm to 90 µm. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 In some instances, the lattice microstructures exhibit a mechanical integrity sufficient to be load bearing, such as for example as a polymeric microneedle (as described below) that can be administered to a subject. Depending on the density of the lattice microstructure, in some embodiments polymeric structures exhibit a mechanical integrity sufficient to carry a load of 0.1 N or more, such as 0.5 N or more, such as 1 N or more, such as 2 N or more, such as 3 N or more, such as 4 N or more, such as 5 N or more, such as 10 N or more, such as 15 N or more, such as 20 N or more, such as 25 N or more, such as 50 N or more, such as 75 N or more and including 100 N or more. In some embodiments, the lattice microstructure includes one or more structural support struts which is positioned within the lattice microstructure to provide increased mechanical integrity, such as where the mechanical integrity is increased by 5% or more, such as by 25% or more and including by 75% or more. For example, the structural support struts may increase the load that the lattice microstructure can carry by 0.5 N or more, such as by 1 N or more, such as by 5 N or more, such as by 10 N or more, such as by 25 N or more, such as by 50 N or more and including by 100 N or more. In some instances, the structural support struts are positioned within the interior of the lattice microstructure. In other embodiments, the support struts are positioned along the exterior of the lattice microstructure. In some instances, the polymeric microneedles are compliant and exhibit a flexible integrity. In some instances, the polymeric microneedles yield under a load bearing. As described above, in some embodiments, the polymeric microneedles may exhibit elastic deformation. Polymeric structures having a lattice microstructure of interest may have a length of from 50 µm to 2000 µm, such as from 75 µm to 1950 µm, such as from 100 µm to 1900 µm, such as from 125 µm to 1850 µm, such as from 150 µm to 1800 µm, such as from 175 µm to 1750 µm, such as from 200 µm to 1700 µm, such as from 225 µm to 1650 µm, such as from 250 µm to 1600 µm, such as from 275 µm to 1550 µm and including from 300 µm to 1500 µm. Polymeric structures having a lattice microstructure of interest may have a width of from 50 µm to 1000 µm, such as from 75 µm to 950 µm, such as from 100 µm to 900 µm, such as from 125 µm to 850 µm, such as from 150 µm to 800 µm, such as from 175 µm to 750 µm, such as from 200 µm to 700 µm, such as from 225 µm to 650 µm, such as from 250 µm to 600 µm, such as from 275 µm to 550 µm and including from 300 µm to 500 µm. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 In some embodiments, the microneedle includes a tip section, a body section and a base section. In embodiments, one or more of the tip section, body section and base section of the polymeric microneedle have a lattice microstructure as described above. In some instances, one or more of the tip section, body section and base section have a solid structure (i.e., interior space that is completely filled). In some instances, one or more of the tip section, body section and base section have a hollow interior space. In certain embodiments, the microneedle includes a tip section having a solid structure, a body section having a lattice microstructure and a base section having a solid structure. In embodiments, the tip section may be a length of from 10 µm to 500 µm, such as from 20 µm to 490 µm, such as from 30 µm to 480 µm, such as from 40 µm to 470 µm, such as from 50 µm to 460 µm, such as from 60 µm to 450 µm, such as from 70 µm to 440 µm, such as from 80 µm to 430 µm, such as from 90 µm to 420 µm, such as from 100 µm to 410 µm, such as from 110 µm to 400 µm, such as from 120 µm to 390 µm, such as from 130 µm to 380 µm, such as from 140 µm to 370 µm and including from 150 µm to 360 µm. In some instances, the microneedle has a tip diameter of from 0.1 µm to 10 µm, such as from 0.5 µm to 9 µm, such as from 1 µm to 8 µm and including from 2 µm to 7 µm. In some embodiments, the body section has a length of from 10 µm to 500 µm, such as from 20 µm to 490 µm, such as from 30 µm to 480 µm, such as from 40 µm to 470 µm, such as from 50 µm to 460 µm, such as from 60 µm to 450 µm, such as from 70 µm to 440 µm, such as from 80 µm to 430 µm, such as from 90 µm to 420 µm, such as from 100 µm to 410 µm, such as from 110 µm to 400 µm, such as from 120 µm to 390 µm, such as from 130 µm to 380 µm, such as from 140 µm to 370 µm and including from 150 µm to 360 µm. In some embodiments, the base section has a length of from 10 µm to 500 µm, such as from 20 µm to 490 µm, such as from 30 µm to 480 µm, such as from 40 µm to 470 µm, such as from 50 µm to 460 µm, such as from 60 µm to 450 µm, such as from 70 µm to 440 µm, such as from 80 µm to 430 µm, such as from 90 µm to 420 µm, such as from 100 µm to 410 µm, such as from 110 µm to 400 µm, such as from 120 µm to 390 µm, such as from 130 µm to 380 µm, such as from 140 µm to 370 µm and including from 150 µm to 360 µm. In some embodiments, the lattice microstructure of the polymeric microneedles is formed from lattice cells having a unit size of from 1 µm to 1000 µm, such as from 5 µm to 950 µm, such as from 10 µm to 900 µm, such as from 15 µm to 850 µm, such as from Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 20 µm to 800 µm, such as from 25 µm to 750 µm, such as from 30 µm to 700 µm, such as from 35 µm to 650 µm, such as from 40 µm to 600 µm, such as from 45 µm to 550 µm and including from 50 µm to 500 µm, for example from 200 µm to 500 µm. In embodiments, the polymeric microneedles has a volume of from 0.01 µL to 25 µL, such as from 0.02 µL to 24.5 µL, such as from 0.03 µL to 24 µL, such as from 0.04 µL to 23.5 µL, such as rom 0.05 µL to 23 µL, such as from 0.6 µL to 22.5 µL, such as from 0.07 µL to 22 µL, such as from 0.08 µL to 21.5 µL, such as from 0.09 µL to 21 µL, such as from 0.1 µL to 20 µL, such as from 0.5 µL to 19 µL, such as from 1 µL to 18 µL, such as from 2 µL to 17 µL, such as from 3 µL to 16 µL and including from 4 µL to 15 µL. In some embodiments, the polymeric microneedle is configured to deliver a volume (e.g., administering an active agent to a subject by injection) of from 0.1 µL to 25 µL, such as from 0.2 µL to 24 µL, such as from 0.3 µL to 23 µL, such as from 0.4 µL to 22 µL, such as rom 0.5 µL to 21 µL, such as from 0.6 µL to 20 µL, such as from 0.7 µL to 19 µL, such as from 0.8 µL to 18 µL, such as from 0.9 µL to 17 µL and including where the lattice microstructure is configured to contain a volume of from 1 µL to 15 µL. Polymeric microneedles may be any three-dimensional geometric shape including but are not limited to: rectilinear cross sectional shapes, e.g., squares, rectangles, trapezoids, triangles, hexagons, etc., curvilinear cross-sectional shapes, e.g., circles, ovals, etc., as well as irregular shapes, e.g., a parabolic bottom portion coupled to a planar top portion. In embodiments, each polymeric microneedle includes a tip section, a body section and a base section. In some instances, each of the tip section, the body section and the base section has the same cross-sectional shape. In some instances, one or more of the tip section, the body section and the base section has a different cross-sectional shape. In some instances, one or more of the tip section, the body section and the base section has a rigid cross cross-sectional shape. In some instances, each of the tip section, the body section and the base section has a rigid cross cross-sectional shape. In some instances, the body section and the base section has a rigid cross cross-sectional shape. In some instances, one or more of the polymeric microneedles has a beveled tip section. In certain instances, the tip section of the polymeric microneedle has a bevel angle of from 1° to 45°, such as from 2° to 40°, such as from 3° to 35°, such as from 4° to 30° and including from 5° to 25°. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 Figure 4A depicts the variation of different three-dimensional geometric shaped components of polymeric microneedles according to certain embodiments. In some instances, the polymeric microneedles have different overall thickness. In some instances, the polymeric microneedles each have different tip shapes. In other instances, the polymeric each have different skewness, such as where the microneedle has one or more sloped edges. For example, the sloped edge may have a slope angle of 5° or more, such as 10° or more, such as 15° or more, such as 20° or more, such as 25° or more, such as 30° or more, such as 45° or more and including a slope edge having a slope angle of 60° or more. In some instances, the polymeric microneedle has sections (tip section, body section, base section) with different cross-sectional shapes as well as position of the different cross-sectional shapes. Figure 4B depicts examples of polymeric microneedles having different cross-sectional shapes and geometric configurations for different sections (e.g., tip, body, base) of the polymeric microneedle according to certain embodiments. In some embodiments, polymeric microneedles of interest have a cross-shaped cross-section. Figure 5A depicts polymeric microneedles having different cross-shaped cross-sections according to certain embodiments. In some instances, the cross shape provides sufficient surface area that may be compared to the quantity of surface area provided by the large circle and square bases of conical and pyramidal microneedle designs, respectively, and may be contrasted to the quantity of surface area provided by the small circle base of cylindrical microneedle designs. In some instances, the cross shape cross-section microneedle design effectively integrates the slim qualities of cylindrical microneedle designs; a cylindrical design is distinguished from a conical design or a pyramidal design for consistent thinness. In regards to the cross cross- section microneedle design, the cross shape cross-section includes an outer and an inner diameter. In some instances, the cross shape cross-sections produce three dimensional protrusions that may be defined as blades. The blades provide for effectiveness in insertion into the skin of a subject and the blades in certain instances provide supplemental sharp features that improve the ability of the microneedle to slice and penetrate the outermost layer of the skin. Figure 5B depicts an example of the effect of cross-section shape of the polymeric microneedles when pressed through a plurality of membrane layers according to certain embodiments. As shown in Figure 5B, Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 polymeric microneedles have a cross-shape cross-section exhibited less puncture damage to the membranes which facilitated less forceful insertion. In certain instances, polymeric microneedles have a tip section that has a conical cross-sectional shape. As described above, the length of the conical tip may vary and may be 1% or more of the total length of the polymeric microneedle, such as 2% or more, such as 3% or more, such as 4% or more, such as 5% or more, such as 10% or more, such as 15% or more, such as 20% or more and including 25% or more of the total length of the polymeric microneedle. Figure 6A depicts polymeric microneedles having different length tip sections having a conical cross-sectional shape. Figure 6B depicts an example of the effect of different length conical tip polymeric microneedles when pressed through a plurality of membrane layers according to certain embodiments. In some embodiments, polymeric microneedles have a biologically-mimicked shape or design, such as from a venomous animal or insect. This shape is based on the discovery by the inventors that the shape and configuration of stingers and fangs from venomous species (e.g., bees, scorpions, snakes, spiders, etc.) can provide for more complete payload delivery, reduced fluid back pressure and reduced payload leakage. In some instances, the biologically-mimicked shape of the polymeric microneedles include a solid needle tip that acts as a shield, protecting the injection port during insertion and preventing any obstruction by flesh during payload injection. In some instances, the biologically mimicked polymeric microneedle includes one or more fluidic microchannels within the microneedle where outlet of the microchannel is protected from clogs. In some embodiments, one or more of the polymeric microneedles has a stinger- type shape or configuration. For example, in some instances one or more of the polymeric microneedles has a bee-stinger shape. In some instances, one or more of the polymeric microneedles has a scorpion-stinger shape. In certain instances, the polymeric microneedle has the stinger-type shape and includes one or more microchannels that has an outlet positioned in the body section of the polymeric microneedle (i.e., one or more outlets positioned away from the tip section of the microneedle). In certain instances, the polymeric microneedle has a bee-stinger shape. In certain embodiments, one or more of the polymeric microneedles has a fang-type shape or configuration. For example, in some instances, one or more of the polymeric microneedles has a snake-fang (e.g., viper) shape or a spider-fang shape. In certain Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 instances, the polymeric microneedle has the fang-type shape and includes one or more microchannels that has an outlet positioned in the body section of the polymeric microneedle (i.e., one or more outlets positioned away from the tip section of the microneedle). Figure 7 depicts example biologically-mimicked shaped designs of polymeric microneedles according to certain embodiments. The biologically-mimicked shapes includes the fangs or stingers of a viper, a jumping spider, a scorpion and a honeybee. In some embodiments, one or more of the polymeric microneedles has a solid tip section and a body section and a base section that includes one or more microfluidic channels. In some instances, the body section has an outlet for one of more of the microfluidic channels. In certain instances, there is no outlet for the microfluidic channel at the tip section of the polymeric microneedle. In some instances, one or more of the tip section, the body section and the base section has a hollow internal space. In some instances, one or more of the polymeric microneedles has: a tip section having a solid structure; a body section having a hollow structure; and a base section having a solid structure. In some embodiments, one or more of the tip section, the body section and the base section are fenestrated. In some instances, the tip section is fenestrated. In some instances, the body section is fenestrated. In some instances, the tip section of the polymeric microneedle includes one or more openings. In some instances, the body section of the polymeric microneedle includes one or more openings. In some instances, the base section of the polymeric microneedle includes one or more openings. In some instances, the opening on the polymeric microneedle is an outlet from one or more microchannels within the polymeric microneedle. The opening may be positioned in some instances, a predetermined distance from the tip of the microneedle, such as 5 µm to 200 µm away from the tip of the microneedle, such as from 7.5 µm to 195 µm, such as from 10 µm to 190 µm, such as from 12.5 µm to 185 µm, such as from 15 µm to 180 µm, such as from 17.5 µm to 175 µm, such as from 20 µm to 170 µm, such as from 22.5 µm to 165 µm, such as from 25 µm to 160 µm, such as from 27.5 µm to 155 µm and including from 30 µm to 150 µm from the tip of the microneedle. Figure 8 depicts polymeric microneedles having a solid tip section and body and base sections which include a microfluidic channel position therethrough according to certain embodiments. As shown in Figure 8, microneedle 800 includes tip section 801, body Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 section 802 and base section 803. Tip section 801 of microneedle 800 is solid and includes no opening. Microchannel 804 is positioned through body section 802 and base section 803 and can be fluidically coupled to a reservoir (as described in greater detail below) or may be filled with an active agent component (e.g., a lyophilized active agent, reconstituted solid active agent or hydrogel containing an active agent positioned in microchannel 804). In some embodiments, polymeric microneedles have a teardrop shape. In some instances, the teardrop shaped microneedle improves retention in skin and increase volumetric cargo loading per needle. Figure 9 depicts examples of teardrop shaped polymeric microneedles according to certain embodiments. Retention of needles in the skin is a barrier to both intradermal drug delivery and interstitial fluid sampling. Needles are constantly under stress as they are inserted into skin, further, they experience viscoelastic recoil and resistance from the skin itself. (Figure 9, right side) As a result, conventional pyramidal designs are often pushed out due to the smooth, angular surface of the needle facilitating release from the skin. To circumvent this issue, we have developed a novel teardrop needle geometry that is completely unmoldable and thus has not been produced by normal injection molding methods. Due to the wider midsection of this design, compared to its base dimension, the needle will have better skin retention and reduced insertion forces. Teardrop shaped polymeric microneedles also incorporate hollow regions to facilitate cargo loading and interstitial sampling. These needle geometries can hold up to 0.08 μL per needle, which is nearly twice more than previously achievable using a simple lattice polymeric microneedle. In some embodiments, polymeric microneedles have a tapered shape. In some instances, the tapered shaped microneedle improve cargo loading and needle adhesion to polymeric structure. Tapered shaped polymeric microneedles are geometries wherein the strut diameter of the needle gradually increases as you move from the needle tip to the patch base. Figure 10 depicts examples of tapered shaped polymeric microneedles according to certain embodiments. Tapered shaped polymeric microneedles in some instances exhibit reduced amount of materials that need to be used and also have increased void volume to improve cargo loading. Tapered shaped polymeric microneedles can load 2.5X more cargo than a simple lattice polymeric microneedle. Further, the increased strut diameter near the base of the needle improves adhesion of Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 needles onto the patch base to facilitate manufacturing via 3D printing and enhances mechanical properties of the needle. This design will reduce the likelihood of needles fracturing at the base and breaking off in skin. In some embodiments, polymeric microneedles have a pillared shape. In some instances, pillared shaped microneedles to improve sealing when inserted into the skin of a subject. Figure 11A depicts examples of pillared shaped polymeric microneedles according to certain embodiments. When delivering polymeric microneedles into the skin of a subject, in some instances cargo can leak out once the needle was inserted past the stratum corneum. Figure 11B depicts a schematic of the retention of cargo delivery in the skin when administered with pillared shaped polymeric microneedles according to certain embodiments. In some instances, a pillared structure helps to seal the microneedle and its cargo in the skin (Figure 11B). These pillars generate a local downward force that can help retain the needle in the skin to facilitate dermal delivery and interstitial fluid sampling. Further, the presence of a pillar distributes force over the base of the needle to improve penetration into the skin. We have since generated several different P-MAPs that integrate this pillar structure to facilitate retention and sealing of the skin (Figure 1.6). Pillars may be chamfered or created in non-uniform geometries to improve skin sealing. Pillars may contain rounded edges to improve skin sealing. Pillared MAPs may be implemented with various needle design geometries. Pillars of different geometries may be implemented across different needles on a patch to modify skin retention and skin sealing effects across the patch. Pillars may also be made to be hollow to serve as reservoirs for cargo. In some embodiments, polymeric microneedles have arrowhead shape. In some instances, arrowhead shaped microneedles improve skin sealing when inserted into the skin of a subject. Figure 12 depicts an example of an arrowhead-shaped polymeric microneedle according to certain embodiments. To utilize the elasticity of the skin to help improve skin sealing, arrowhead shaped polymeric microneedles may be generated with components that have varying widths near the base across the insertion length of the needle to create a structure resembling an arrowhead. The narrower portion near the base may be used for the skin to seal around after insertion holding the arrowhead shaped polymeric microneedle in place as it delivers cargo. This will help to prevent unintentional needle retraction out of the skin during administration. In turn, this will help Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 to prevent cargo leakage out of the pore created by the microneedle. The arrowhead portion (thicker, then thinner, then thicker width) may be implemented with various needle design geometries to help improve skin sealing. Arrowhead shaped polymeric microneedles may be implemented with pillars as well and with needles of various geometries. In some embodiments, polymeric microneedles have a bevel shape. In some instances, beveled microneedles improve skin insertion and sealing. In certain instances, the tip section of the polymeric microneedle has a bevel angle of from 1° to 45°, such as from 2° to 40°, such as from 3° to 35°, such as from 4° to 30° and including from 5° to 25°. For example, the sloped edge of the bevel-shaped polymeric microneedle may have a slope angle of 5° or more, such as 10° or more, such as 15° or more, such as 20° or more, such as 25° or more, such as 30° or more, such as 45° or more and including a slope edge having a slope angle of 60° or more. Figure 13 depicts examples of bevel-shaped polymeric microneedles according to certain embodiments. There may be various degrees of beveling of different needles across a patch to allow for modifications to skin stretching as needles are inserted. The different degrees of beveling may be accompanied by different heights of needles across the polymeric structure (as described above). The beveled needles may include internal structures such as struts for support (Figure 13, bottom polymeric microstructure array). In some embodiments, injection of liquid into the skin using microneedles that are beveled and straight results in liquid backflow onto the skin surface. In some embodiments, the polymeric structure includes beveled microneedles that are slanted. Slanted microneedles allow for an injection point that is further in the skin. With straight microneedles, the liquid is injected in a position where it can flow upwards in the gap between where the needles are inserted into the skin. Using the slanted microneedles, the liquid might also flow upwards but will be trapped in the skin better due to the lack of an opening immediately above the injection point. This allows for the benefits of microneedle delivery while taking advantage of aspects of what make a traditional intradermal injection work (Figure 13). In some embodiments, one or more of the polymeric microneedles is positioned at an angle of 5° to 60° with respect to the skin surface of the subject, such as from 10° to 55°, such as from 15° to 50°, such as from Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 20° to 45° and including being slanted from 25° to 40° with respect to the skin surface of the subject. In some embodiments, polymeric are fenestrated. In some instances, fenestrated microneedles maximize interstitial fluid flow rate. Figure 14 depicts examples of fenestrated polymeric microneedles according to certain embodiments. Facile sampling of interstitial fluid in some instances uses the application of a pressure gradient to accelerate fluid flow, a large opening area on the microneedle to receive the fluid, and a flow channel within the microneedle to direct fluid to a collection chamber. Conventional hypodermic needles manufactured by tube drawing are constrained with fixed ratios between the opening area, channel width, and wall thickness, and fluid can only be drawn at a fixed depth at the needle tip. fenestrated microneedles are hollow microneedles designed with multiple openings on the side to maximize the surface area for receiving fluid from multiple depths and directions. Large opening areas are possible even with a thin channel width because the two are decoupled. The wall thickness of the microneedle can be varied along its length according to functional needs, with a solid tip for skin penetration and reinforced thick walls in the body of the microneedle to resist bending (Figure 14). This type of design is not possible to manufacture by molding or tube drawing. In some embodiments, one or more of the polymeric microneedles are in fluid communication with a reservoir. In some instances, the reservoir is part of a backing structure for the polymeric structure. In some instances, the reservoir is an integrated component of the polymeric structure. In some instances, each polymeric microneedle is in fluidic communication with a distinct reservoir. In some instances, the distinct reservoirs are in fluid communication with each other through one or more microchannels positioned in the backing structure. In some instances, the polymeric microneedle is in fluidic communication with the one or more reservoirs through a microfluidic channel which outlets from a body section or base section of the polymeric microneedle (e.g., to deliver an active agent to a subject or to collect a biological sample from the subject). In some instances, each polymeric microneedle includes a microfluidic channel coupled to a fluidic channel which runs through the base section and body section of the microneedle (as described above). In some instances, the microfluidic channel includes a branched structure such as where downstream Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 distributors branch from the channel which is in fluid communication with the fluidic channel which runs through the base and body sections of the microneedle. In some instances, the branched structure includes 2 or more branches, such as 4 or more, such as 8 or more, such as 16 or more and including 32 or more branched channels. In some instances, the polymeric structure includes a connector component such as to couple a reservoir to aid in the delivery of a dry or liquid sample to the polymeric structure. In some instances, the polymeric structure may be modified to include various components in the backing of the patch including reservoirs to hold liquid or dry products and protect them during storage, handling, and administration. The use of a reservoir allows for storage and delivery of products requiring doses higher than what can be loaded onto a traditional microarray patch with no backing. This reservoir may be connected to the needles on the patch via low dead volume microfluidic channels that enable even distribution and delivery of the dose upon administration. The low dead volume channels may be printed utilizing high resolution injection continuous liquid interface production as described in detail below. In certain instances, the connector component is a Luer lock-type connection. A Luer lock connection may be implemented to allow for secure connection of a backing structure component to aid in delivery of a dry or liquid product. For example, in the case of a dry product, a Luer lock syringe may be attached and used to apply a reconstitution liquid to the dry product to help reconstitute and deliver the payload. In some instances, the polymeric microstructure includes and integrated microfluidic network. In some instances, the ability of a microfluidic backing to control the transport of small volumes of fluid while varying reaction conditions will allow the polymeric structure to achieve new drug delivery capabilities. In some instances, microfluidic-backed polymeric structures enable the delivery of a controlled amount of payload at any volume. For example, a microfluidic-backed polymeric structures can be designed to integrate a reservoir in the microfluidic backing to allow for the liquid payload to be stored in the microneedles but also into the microfluidic backing. Figure 15A depicts a polymeric structure having a fluidic reservoir in fluid communication with polymeric microneedles according to certain embodiments. In some instances, the reservoir is a single large reservoir in fluidic communication with all of the microneedles of the polymeric structure (Figure 15A, left). In other instances, each microneedle is in Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 fluid communication with an individual reservoir (Figure 15A, right). Figure 15B depicts coupling the polymeric structure with a reservoir through a connector (e.g., a Luer lock connection) according to certain embodiments. The reservoir is in fluidic communication with the microneedles of the polymeric structure and are fastened with the connector so that no fluid leakage occurs. Figure 16 depicts a microfluidic distribution system for integrating/connecting to a polymeric microstructure having a plurality of microneedles according to certain embodiments. In some instances, the microfluidic distribution system is configured to connect each microneedle on the polymeric structure to a single input (syringe, etc.) (Figure 16). In some instances, the single input even distributes the inputted composition into 2 or more microneedles, such as 4 or more, such as 8 or more, such as 12 or more, such as 16 or more, such as 20 or more, such as 24 or more, such as 28 or more and including 32 or more microneedles. In some embodiments, the microfluidic distribution system is coupled to an active input component, such as a pump. Figure 17 depicts an active injection pump that applies positive pressure to convey a composition in the microfluidic channel system and through the polymeric microneedles. In some instances, the pump system provides for varying liquid delivery conditions at the point of delivery. Microfluidic-backed polymeric microstructures according to some embodiments are configured with a fluidic network that controls the flow rate (e.g., for faster or slower payload delivery, etc.) of liquid payload being inserted into the dermis at any point in time. For example, microfluidic networks can be connected to an external pressure source to control the flow rate of injection (Figure 17). In some instances, the microfluidic channels are configured to provide for control of the flow rate for conveying a composition. In some instances, the microfluidic channels include narrowing diameters, tortuous flow paths or other convenient methods for delaying or increasing the flow rate for composition conveyance. Figure 18 depicts microfluidic channel configurations for controlling flow rate according to certain embodiments. For example, microfluidic channel diameters can be narrowed or widened at various points in the microfluidic backing to achieve the desired flow rate distribution. Similarly, tortuous microfluidic channels can be introduced to control the rate of composition conveyance. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 In some instances, the microfluidic channels are configured for mixing or combining compositions for conveying through the microneedles of the polymeric structure. In some instances, the microfluidic channel network can be used to directly mix payloads together at the point of delivery. For example, a microfluidic network could enable complete mixing of payloads with tunable mixing ratio. Figure 19 depicts examples of microfluidic channels which are configured for mixing or combining compositions and delivering the mixed compositions through microneedles of the polymeric structure. In certain instances, the microfluidic channels are configured to be used to directly synthesize nanoparticles with tunable physiochemical properties (size, homogeneity, drug loading) at the point of delivery. Figure 20 depicts in situ synthesis using microfluidic channels in fluid communication with a microneedle of a polymeric structure according to certain embodiments. As shown in Figure 20, first and second reagents are conveyed through microfluidic channels of the network and a third reagent is conveyed through a third microfluidic channel. The synthesized composition is generated in situ and delivered through a microneedle of the polymeric structure. In certain instances, the first and second reagents are transfer media and the third reagent is a nanoparticle composition where nanoparticles are generated in situ in the microfluidic channel and delivered through the microneedle. In some instances, the microfluidic channel network is configured to deliver a plurality of active agent compounds through an array of microneedles of the polymeric structure. For example, this may provide for multiple treatment co-dosing according to certain embodiments. In some instances, a microfluidic channel network orchestrates delivering multiple liquid payloads to a patient through a single polymeric structure having an array of microneedles. Figure 21 depicts an example of delivering a plurality of different compositions (e.g., different active agents) through an array of microneedles according to certain embodiments. In some embodiments, the microfluidic channel network is configured to deliver 2 or more different compositions, such as 3 or more, such as 4 or more, such as 5 or more, such as 6 or more, such as 7 or more, such as 8 or more, such as 9 or more, such as 10 or more, such as 15 or more, such as 20 or more, such as 25 or more and including 30 or more different compositions. In some embodiments, the polymeric structure includes a microfluidic channel network configured for convective in-situ reconstitution of a solid compound (e.g., Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 lyophilized compound). In some instances, the polymeric structure-microfluidic channel introduces an active convective force to achieve reconstitution of a liquid composition. Lyophilization – Various biologic cargos may be lyophilized (freeze-dried) inside of the microneedles of the polymeric structure. Using this approach, the liquid formulation of the composition may be loaded into the microneedles using various methods such as dip coating and backfilling through a microfluidic backing. Formulations may include small molecule active agents, biologics, as well as cryoprotectants or cake-forming agents. The liquid filled microneedles may be frozen and then lyophilized (freeze-dried) directly. The struts and structure of the polymeric microneedle provides a cage for the lyophilized formulation (cake) to be retained. Figure 22 depicts polymeric microneedles having an incorporated lyophilized composition according to certain embodiments. In some instances, the lyophilized composition includes betadine (Figure 22, right). In some instances, the lyophilized composition does not include betadine (Figure 22, left). In some instances, the polymeric structure and microfluidic channel network are configured for reconstituting a lyophilized composition. In some instances, to achieve an active reconstitution the polymeric structure-microfluidic channel generates convective driving forces of reconstitution liquids. Figure 23 depicts liquid injection reconstitution of a lyophilized composition with a polymeric structure and microfluidic channel network according to certain embodiments. First, a reconstitution liquid (e.g., water, saline, PBS, etc.) can be applied to the polymeric structure and microfluidic channel network using a syringe, a plunger, a bladder, or other fluid delivery devices. Upon administration of the microfluidic-backed MAPs to the skin, the fluid may be released into the space where the lyophilized formulation is (needles, microfluidic channels, reservoir) to allow for rehydration of the lyophilized formulation (cake). Fluid or pressure may be used to drive the reconstituted cargo out of the microneedles, microfluidic channels, or reservoirs. Figure 24 depicts using pressure fields in a polymeric structure and microfluidic channel network to reconstitute a lyophilized composition according to certain embodiments. In some instances, a controlled volume of liquid is administered to rehydrate and disperse the lyophilized composition in the skin. Next, a negative pressure field is applied through the microfluidic backing to draw a reconstitution liquid (such as interstitial fluid) to the lyophilized sample. Upon reconstitution, a positive pressure will then be exerted through the microfluidic network forcing the reconstitution Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 back through the microneedles. In some instances, this approach requires no additional reconstitution liquid to be added to the system while still generating a convective dissolution force driving faster reconstitution. Figure 25 depicts using a hydrogel to reconstitute a lyophilized composition in polymeric microneedles according to certain embodiments. In some instances, the polymeric structure and microfluidic channel network generate interstitial fluid convection in the skin. For example, some microneedles in the middle of the polymeric structure are filled with a dry, hydroscopic hydrogel and the peripheral needles are filled with lyophilized cakes. This design is configured so that as the hydrogel attracts interstitial fluid it creates flow/convection locally in the patch area helping with dissolution and cargo release. In embodiments, the polymeric structure is formed from a polymerizable material which may include but is not limited to polycaprolactone, polyglycolic acid, polylactic acid, polylactic-co-glycolic acid, polyethylene glycol, thiol-enes, anhydrides, polyacrylic acid, poly methylmethacrylate, polyvinyl alcohol, polyvinylpyrrolidone, vinyl carbonates, vinyl esters, acrylamides, hyaluronic acid, chitosan, collagen, gelatin, carboxymethylcellulose, and blends or copolymers thereof. In certain embodiments, the polymeric structure is formed from polyethylene glycol dimethacrylate (PEGDMA). In certain embodiments, the polymeric structure is formed from trimethylolpropane triacrylate (TMPTA) monomer. In certain embodiments, the polymerizable material is selected from polycarbonates, polyvinyl chloride (PVC), polyurethanes, polyethers, polyamides, polyimides, or copolymers of these thermoplastics, such as PETG (glycol- modified polyethylene terephthalate), among other polymeric plastic materials. In certain embodiments, the beamsplitter is formed from a polyester, where polyesters of interest may include, but are not limited to, poly(alkylene terephthalates) such as poly(ethylene terephthalate) (PET), bottle-grade PET (a copolymer made based on monoethylene glycol, terephthalic acid, and other comonomers such as isophthalic acid, cyclohexene dimethanol, etc.), poly(butylene terephthalate) (PBT), and poly(hexamethylene terephthalate); poly(alkylene adipates) such as poly(ethylene adipate), poly(1,4-butylene adipate), and poly(hexamethylene adipate); poly(alkylene suberates) such as poly(ethylene suberate); poly(alkylene sebacates) such as poly(ethylene sebacate); poly(ε-caprolactone) and poly(β-propiolactone); poly(alkylene isophthalates) such as Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 poly(ethylene isophthalate); poly(alkylene 2,6-naphthalene-dicarboxylates) such as poly(ethylene 2,6-naphthalene-dicarboxylate); poly(alkylene sulfonyl-4,4′-dibenzoates) such as poly(ethylene sulfonyl-4,4′-dibenzoate); poly(p-phenylene alkylene dicarboxylates) such as poly(p-phenylene ethylene dicarboxylates); poly(trans-1,4- cyclohexanediyl alkylene dicarboxylates) such as poly(trans-1,4-cyclohexanediyl ethylene dicarboxylate); poly(1,4-cyclohexane-dimethylene alkylene dicarboxylates) such as poly(1,4-cyclohexane-dimethylene ethylene dicarboxylate); poly([2.2.2]- bicyclooctane-1,4-dimethylene alkylene dicarboxylates) such as poly([2.2.2]- bicyclooctane-1,4-dimethylene ethylene dicarboxylate); lactic acid polymers and copolymers such as (S)-polylactide, (R,S)-polylactide, poly(tetramethylglycolide), and poly(lactide-co-glycolide); and polycarbonates of bisphenol A, 3,3′-dimethylbisphenol A, 3,3′,5,5′-tetrachlorobisphenol A, 3,3′,5,5′-tetramethylbisphenol A; polyamides such as poly(p-phenylene terephthalamide); polyethylene Terephthalate (e.g., MylarTM Polyethylene Terephthalate), combinations thereof, and the like. In some embodiments, the polymeric structures are formed from a polymerizable material which is biodegradable. The term “biodegradable” is used herein in its conventional sense to refer to a material which is capable of being decomposed, broken down or degraded by a living organism, such as microorganisms for example bacteria. In certain embodiments, the polymerizable material is dissolvable in an aqueous medium. In embodiments where the polymeric structure is formed from a dissolvable material, the lattice microstructure may be dissolved in water over a period of time of 0.01 hours or more, such as over 0.05 hours or more, such as over 0.1 hours or more, such as over 0.5 hours or more, such as over 1 hour or more, such as over 2 hours or more, such as over 6 hours or more, such as over 12 hours or more, such as over 18 hours or more, such as over 24 hours or more, such as over 36 hours or more, such as over 48 hours or more, such as over 72 hours or more, such as over 96 hours or more, such as over 120 hours or more, such as over 144 hours or more and including over 168 hours or more. Active agent compounds of interest include but are not limited to organic materials such as horseradish peroxidase, phenolsulfonphthalein, nucleotides, nucleic acids (e.g., oligonucleotides, polynucleotides, siRNA, shRNA), aptamers, antibodies or portions thereof (e.g., antibody-like molecules), hormones (e.g., insulin, testosterone), Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 growth factors, enzymes (e.g., peroxidase, lipase, amylase, organophosphate dehydrogenase, ligases, restriction endonucleases, ribonucleases, RNA or DNA polymerases, glucose oxidase, lactase), cells (e.g., red blood cells, stem cells), bacteria or viruses, other proteins or peptides, small molecules (e.g., drugs, dyes, amino acids, vitamins, antioxidants), lipids, carbohydrates, chromophores, light emitting organic compounds (such as luciferin, carotenes) and light emitting inorganic compounds (e.g., chemical dyes and/or contrast enhancing agents such as indocyanine green), immunogenic substances such as vaccines, antibiotics, antifungal agents, antiviral agents, therapeutic agents, diagnostic agents or pro-drugs, analogs or combinations of any of the foregoing. Examples of immunogenic vaccine substances that can be included in the microneedles described herein include, but are not limited to, those in BIOTHRAX® (anthrax vaccine adsorbed, Emergent Biosolutions, Rockville, Md.); TICE® BCG Live (Bacillus Calmette-Guerin for intravesical use, Organon Tekina Corp. LLC, Durham, N.C.); MYCOBAX® BCG Live (Sanofi Pasteur Inc); DAPTACEL® (diphtheria and tetanus toxoids and acellular pertussis [DTaP] vaccine adsorbed, Sanofi Pasteur Inc.); INFANRIX® (DTaP vaccine adsorbed, GlaxoSmithKline); TRIPEDIA® (DTaP vaccine, Sanofi Pasteur); TRIHIBIT® (DTaP/Hib, sanofi pasteur); KINRIX® (diphtheria and tetanus toxoids, acellular pertussis adsorbed and inactivated poliovirus vaccine, GlaxoSmithKline); PEDIARIX® (DTaP-HepB-IPV, GlaxoSmithKline); PENTACEL® (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b conjugate [tetanus toxoid conjugate] vaccine, sanofi pasteur); Diphtheria and Tetanus Toxoids, adsorbed (for pediatric use, Sanofi Pasteur); DECAVAC® (diphtheria and tetanus toxoids adsorbed, for adult use, Sanofi Pasteur); ACTHIB® (Haemophilus b tetanus toxoid conjugate vaccine, Sanofi Pasteur); PEDVAXHIB® (Hib vaccine, Merck); Hiberix (Haemophilus b tetanus toxoid conjugate vaccine, booster dose, GlaxoSmithKline); COMVAX® (Hepatitis B-Hib vaccine, Merck); HAVRIX® (Hepatitis A vaccine, pediatric, GlaxoSmithKline); VAQTA® (Hepatitis A vaccine, pediatric, Merck); ENGERIX-B® (Hep B, pediatric, adolescent, GlaxoSmithKline); RECOMBIVAX HB® (hepatitis B vaccine, Merck); TWINRIX®, (HepA/HepB vaccine, 18 years and up, GlaxoSmithKline); CERVARIX® (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant, GlaxoSmithKline); Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 GARDASIL® (human papillomavirus bivalent [types 6, 11, 16 and 18] vaccine, recombinant, Merck); AFLURIA® (Influenza vaccine, 18 years and up, CSL); AGRIFLU™ (influenza virus vaccine for intramuscular injection, Novartis Vaccines); FLUARIX® (Influenza vaccine, 18 years and up, GlaxoSmithKline); FLULAVAL® (Influenza vaccine, 18 years and up, GlaxoSmithKline); FLUVIRIN® (Influenza vaccine, 4 years and up, Novartis Vaccine); FLUZONE® (Influenza vaccine, 6 months and up, Sanofi Pasteur); FLUMIST® (Influenza vaccine, 2 years and up, MedImmune); IPOL® (e-IPV polio vaccine, sanofi Pasteur); JE VAX® (Japanese encephalitis virus vaccine inactivated, BIKEN, Japan); IXIARO® (Japanese encephalitis virus vaccine inactivated, Novartis); MENACTRA® (Meningococcal [Groups A, C, Y and W-135] and diphtheria vaccine, Sanofi Pasteur); MENOMUNE®-A/C/Y/W-135 (Meningococcal polysaccharide vaccine, sanofi pasteur); MMRII® (MMR vaccine, Merck); MENVEO® (Meningococcal [Groups A, C, Y and W-135] oligosaccharide diphtheria CRM 197 conjugate vaccine, Novartis Vaccines); PROQUAD® (MMR and varicella vaccine, Merck); PNEUMOVAX 23® (pneumococcal polysaccharide vaccine, Merck); PREVNAR® (pneumococcal vaccine, 7-valent, Wyeth/Lederle); PREVNAR-13® (pneumococcal vaccine, 13-valent, Wyeth/Lederle); POLIO VAX™ (poliovirus inactivated, sanofi pasteur); IMOVAX® (Rabies vaccine, Sanofi Pasteur); RABAVERT™ (Rabies vaccine, Chiron); ROTATEQ® (Rotavirus vaccine, live, oral pentavalent, Merck); ROTARIX® (Rotavirus, live, oral vaccine, GlaxoSmithKline); DECAVAC™ (tetanus and diphtheria toxoids vaccine, sanofi pasteur); Td (generic) (tetanus and diphtheria toxoids, adsorbed, Massachusetts Biol. Labs); TYPHIMV1® (typhoid Vi polysaccharide vaccine, Sanofi Pasteur); ADACEL® (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis, sanofi pasteur); BOOSTRIX® (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis, GlaxoSmithKline); VIVOTIF® (typhoid vaccine live oral Ty21a, Bema Biotech); ACAM2000™ (Smallpox (vaccinia) vaccine, live, Acambis, Inc.); DRYVAX® (Smallpox (vaccinia) vaccine); VARIVAX® (varicella [live] vaccine, Merck); YF-VAX® (Yellow fever vaccine, Sanofi Pasteur); ZOSTAVAX®, (Varicella zoster, Merck); or combinations thereof. Any vaccine products listed in database of Center for Disease Control and Prevention (CDC) can also be included in the compositions described herein. The term small molecule is used herein in its conventional sense to refer to natural or synthetic molecules including, but not limited to, peptides, peptidomimetics, Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, aptamers, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds. The term “antibiotic” is used herein to describe a compound that acts as an antimicrobial, bacteriostatic, or bactericidal agent. Example antibiotics include, but are not limited to, penicillins, cephalosporins, penems, carbapenems, monobactams, aminoglycosides, sulfonamides, macrolides, tetracyclins, lincosides, quinolones, chloramphenicol, vancomycin, metronidazole, rifampin, isoniazid, spectinomycin, trimethoprim, and sulfamethoxazole. In some embodiments, the active agent compound includes but is not limited to steroids and esters of steroids (e.g., estrogen, progesterone, testosterone, androsterone, cholesterol, norethindrone, digoxigenin, cholic acid, deoxycholic acid, and chenodeoxycholic acid), boron-containing compounds (e.g., carborane), chemotherapeutic nucleotides, drugs (e.g., antibiotics, antivirals, antifungals), enediynes (e.g., calicheamicins, esperamicins, dynemicin, neocarzino statin chromophore, and kedarcidin chromophore), heavy metal complexes e.g., cisplatin), hormone antagonists (e.g., tamoxifen), non-specific (non-antibody) proteins (e.g., sugar oligomers), oligonucleotides antisense oligonucleotides that bind to a target nucleic acid sequence (e.g., mRNA sequence)), peptides, proteins, antibodies, photodynamic agents (e.g., rhodamine 123), radionuclides (e.g., I-131, Re-186, Re-188, Y-90, Bi-212, At-211, Sr-89, Ho-166, Sm-153, Cu-67 and Cu-64), toxins (e.g., ricin), and transcription-based pharmaceuticals. In certain embodiments, the polymeric microneedles include active agent compounds selected from acetaminophen, non-steroidal anti-inflammatory medications (NSAIDs), corticosteroids; narcotics; anti-convulsants; local anesthetics, and any combinations thereof. In various aspects of the microneedles provided herein include, but not limited to, ibuprofen, naproxin, aspirin, fenoprofen, flurbiprofen, ketoprofen, Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 oxaprozin, diclofenac sodium, etodolac, indomethacin, ketorolac, sulindac, tolmetin, meclofenamate, mefenamic acid, nabumetone, piroxicam and COX-2 inhibitors. In some instances, the pain medications can include acetaminophen combinations (e.g., acetaminophen with a narcotic) such as acetaminophen with codeine; acetaminophen with hydrocodone; and acetaminophen with oxycodone. In some instances, the active agent compound is coated onto one or more surfaces of the microneedle. In some instances, the active agent compound is coated onto a tip section of the microneedle. In some instances, the active agent compound is coated onto a body section of the microneedle. In some instances, the active agent compound is coated onto a base section of the microneedle. In some embodiments, the active agent compound is contained within the lattice microstructure of the polymeric microneedle. In some embodiments, the active agent compound fills 1% or more of the void volume of the lattice microstructure, such as 2% or more, such as 3% or more, such as 4% or more, such as 5% or more, such as 6% or more, such as 7% or more, such as 8% or more, such as 9% or more, such as 10% or more, such as 15% or more, such as 20% or more, such as 25% or more and including 50% or more of the void volume of the lattice microstructure. In some embodiments, each polymeric microneedle contains 0.01 µL or more of the active agent compound, such as 0.05 µL or more, such as 0.1 µL or more, such as 0.2 µL or more, such as 0.3 µL or more, such as 0.4 µL, such as 0.5 µL or more, such as 1 µL or more, such as 2 µL or more, such as 3 µL or more, such as 4 µL or more, such as 5 µL and including 10 µL or more of the active agent compound. In some embodiments, the polymeric microneedles are configured to release active agent compound over a period of time of 0.01 hours or more, such as over 0.05 hours or more, such as over 0.1 hours or more, such as over 0.5 hours or more, such as over 1 hour or more, such as over 2 hours or more, such as over 6 hours or more, such as over 12 hours or more, such as over 18 hours or more, such as over 24 hours or more, such as over 36 hours or more, such as over 48 hours or more, such as over 72 hours or more, such as over 96 hours or more, such as over 120 hours or more, such as over 144 hours or more and including over 168 hours or more. In certain instances, active agent compound is released from the microneedles upon insertion or over a period of time, such as where the active agent compound is released from the microneedle over a time period of about 1 minute to about 6 months, over a time period Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 of about 1 minute to about 3 months, over a time period of about 1 minute to about 1 month, over a time period of about 1 minute to about 2 weeks, over a time period of about 1 minute to about 1 week, over a time period of about 1 minute to about 3 days, over a time period of about 1 minute to about 1 day, over a time period of about 1 minute to about 12 hours, over a time period of about 1 minute to about 6 hours, over a time period of about 1 minute to about 1 hour, over a time period of about 1 minute to about 30 minutes, over a time period of about 30 minutes to about 6 months, over a time period of about 1 hour to about 6 months, over a time period of about 6 hours to about 6 months, over a time period of about 12 hours to about 6 months, over a time period of about 1 day to about 6 months, over a time period of about 3 days to about 6 months, over a time period of about 1 week to about 6 months, over a time period of about 2 weeks to about 6 months, over a time period of about 1 month to about 6 months, or over a time period of about 3 months to about 6 months. In certain embodiments, the active agent compound is released from the microneedle over a time period of less than about 1 minute, over a time period of about 1 second to about 1 minute, over a time period of about 1 second to about 30 seconds, over a time period of about 1 second to about 10 seconds, over a time period of about 10 seconds to about 1 minute or over a time period of about 30 seconds to about 1 minute. In certain embodiments, the active agent compound further includes one or more excipients, such as one or more pharmaceutically acceptable excipients. In certain embodiments, the excipients include a stabilizing excipient. In certain instances, the excipient allows for dissolution of the active agent compound. A wide variety of pharmaceutically acceptable excipients is known in the art and need not be discussed in detail herein. Pharmaceutically acceptable excipients have been amply described in a variety of publications, including, for example, A. Gennaro (2000) “Remington: The Science and Practice of Pharmacy”, 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems (1999) H. C. Ansel et al., eds 7th ed., Lippincott, Williams, & Wilkins; and Handbook of Pharmaceutical Excipients (2000) A. H. Kibbe et al., eds., 3rd ed. Amer. Pharmaceutical Assoc. For example, the one or more excipients may include sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate or calcium carbonate, a binder (e.g., cellulose, methylcellulose, hydroxymethylcellulose, polypropylpyrrolidone, polyvinylpyrrolidone, Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 gelatin, gum arabic, poly(ethylene glycol), sucrose or starch), a disintegrator (e.g., starch, carboxymethylcellulose, hydroxypropyl starch, low substituted hydroxypropylcellulose, sodium bicarbonate, calcium phosphate or calcium citrate), a lubricant (e.g., magnesium stearate, light anhydrous silicic acid, talc or sodium lauryl sulfate), a flavoring agent (e.g., citric acid, menthol, glycine or orange powder), a preservative (e.g., sodium benzoate, sodium bisulfite, methylparaben or propylparaben), a stabilizer (e.g., citric acid, sodium citrate or acetic acid), a suspending agent (e.g., methylcellulose, polyvinylpyrrolidone or aluminum stearate), a dispersing agent (e.g., hydroxypropylmethylcellulose), a diluent (e.g., water), and base wax (e.g., cocoa butter, white petrolatum or polyethylene glycol). The active agent compound may be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable carriers or diluents, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as powders, granules, solutions, injections, inhalants. In certain embodiments, the active agent compound is formulated for injection. For example, compositions of interest may be formulated for interstitial or dermal administration. In pharmaceutical dosage forms, the active agent compound may be administered in the form of its pharmaceutically acceptable salts, or it may also be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds. The following methods and excipients are merely exemplary and are in no way limiting. In some embodiments, compositions of interest include an aqueous buffer. Suitable aqueous buffers include, but are not limited to, acetate, succinate, citrate, and phosphate buffers varying in strengths from about 5 mM to about 100 mM. In some embodiments, the aqueous buffer includes reagents that provide for an isotonic solution. Such reagents include, but are not limited to, sodium chloride; and sugars e.g., mannitol, dextrose, sucrose, and the like. In some embodiments, the aqueous buffer further includes a non-ionic surfactant such as polysorbate 20 or 80. In some instances, compositions of interest further include a preservative. Suitable preservatives include, but are not limited to, a benzyl alcohol, phenol, chlorobutanol, benzalkonium chloride, and the like. In many cases, the composition is stored at about 4°C. Formulations may also be lyophilized, in which case they generally include cryoprotectants such as Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 sucrose, trehalose, lactose, maltose, mannitol, and the like. Lyophilized formulations can be stored over extended periods of time, even at ambient temperatures. In some embodiments, compositions include other additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators, such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents. Where the composition is formulated for injection (subcutaneous or dermal injection), the active agent compound may be formulated by dissolving, suspending or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives. In some instances, the polymeric structures are configured for collecting a biological fluid sample from a subject. The biological fluid sample collected may include fluid from one or more of the subcutis, dermis and epidermis, including the stratum corneum, stratum germinativum, stratum spinosum and stratum basale of the subject. In certain instances, the biological fluid sample is interstitial fluid. In certain instances, the biological fluid sample is dermal fluid. In certain instances, the biological fluid sample is blood. In some embodiments, the collected biological fluid sample from the subject (e.g., interstitial fluid, dermal fluid) is for detecting an analyte present in the biological sample, such as for detecting glucose. In some embodiments, the polymeric microneedle is configured to wick biological fluid into the microneedle such as through capillary action. Depending on the size of the lattice microstructure, the polymeric microneedle may be configured to collect 0.01 µL or more of the biological fluid, such as 0.05 µL or more, such as 0.1 µL or more, such as 0.2 µL or more, such as 0.3 µL or more, such as 0.4 µL, such as 0.5 µL or more, such as 1 µL or more, such as 2 µL or more, such as 3 µL or more, such as 4 µL or more, such as 5 µL and including 10 µL or more of the biological fluid. The biological fluid may be collected into the polymeric microneedle over a period of time of 1 second or more, Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 such as 5 seconds or more, such as 10 seconds or more, such as 15 seconds or more, such as 30 seconds or more, such as 1 minute or more, such as 5 minutes or more, such as 10 minutes or more, such as 15 minutes or more, such as 30 minutes or more, such as 1 hour or more, such as 2 hours or more, such as 3 hours or more, such as 6 hours or more, such as 12 hours or more, such as 18 hours or more and including over a period of time of 24 hours or more. In some instances, the biological fluid is collected using the microneedles of the polymeric structures described herein by one or more of diffusion, capillary action, osmosis, and pressure-driven convection. In some instances, the microneedles of the polymeric structure are configured to induce pressure-driven convection to extract the biological fluid (e.g., interstitial fluid). In some instances, the polymeric structure with microneedles and microfluidic channel network are configured to exert negative pressure which will actively draw the biological fluid (e.g., interstitial fluid out of the dermis through the microneedles and into the microfluidic channel network. Figure 26 depicts the active extraction of interstitial fluid through microneedles and a microfluidic channel network according to certain embodiments. Interstitial fluid is drawn (e.g., by capillary action) through the microneedles and conveyed through the microfluidic channels into an external biological fluid reservoir. In some instances, the polymeric structure and microfluidic channel network is configured to create a pressure gradient across the dermis. A pressure gradient can be created within the dermis to drive fluid flow toward the microneedles of the polymeric structure by the direct application of positive pressure to the skin at the periphery of the MAP patch and negative pressure at the center. In some embodiments, the flow rate is determined by the gradient field, which can be engineered by the shape of the pressure applicator. In some instances, the flow of biological fluid through the center microneedles would be higher. In some instances, the microneedles and microfluidic channel network generate a driving force using electrohydrodynamic force. For example, applying a DC electric field (such as up to 8 kV/mm) between electrodes ionizes a dielectric liquid within the tube, creating negatively charged ions as liquid molecules accept electrons. These ions are accelerated toward the positive electrode, where they discharge. As they move, they set in motion the surrounding liquid molecules to create a net fluid flow. While the dielectric fluid needs to be nonconductive or the voltage cannot be sustained. A vacuum Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 is generated in order to draw biological fluid up through the microneedles. Figure 27 depicts the use of electrodes within a microfluidic network to generate electrohydrodynamic extraction of biological fluid through microneedles of a polymeric structure according to certain embodiments. In certain embodiments, polymeric structures as described above further include a backing layer. The backing layer may be flexible, such as so that it can be brought into close contact with the desired application site on the subject. The backing may be fabricated from a material that does not absorb the active agent compound or biological fluid collected from a subject into the microneedles, and does not allow the active agent compound to be leached from the interior of the lattice microstructure of the polymeric microneedles. Backing layers of interest may include, but are not limited to, non-woven fabrics, woven fabrics, films (including sheets), porous bodies, foamed bodies, paper, composite materials obtained by laminating a film on a non-woven fabric or fabric, and combinations thereof. Non-woven fabric may include polyolefin resins such as polyethylene and polypropylene; polyester resins such as polyethylene terephthalate, polybutylene terephthalate and polyethylene naphthalate; rayon, polyamide, poly(ester ether), polyurethane, polyacrylic resins, polyvinyl alcohol, styrene-isoprene-styrene copolymers, and styrene-ethylene-propylene-styrene copolymers; and combinations thereof. Fabrics may include cotton, rayon, polyacrylic resins, polyester resins, polyvinyl alcohol, and combinations thereof. Films may include polyolefin resins such as polyethylene and polypropylene; polyacrylic resins such as polymethyl methacrylate and polyethyl methacrylate; polyester resins such as polyethylene terephthalate, polybutylene terephthalate and polyethylene naphthalate; and besides cellophane, polyvinyl alcohol, ethylene-vinyl alcohol copolymers, polyvinyl chloride, polystyrene, polyurethane, polyacrylonitrile, fluororesins, styrene-isoprene-styrene copolymers, styrene-butadiene rubber, polybutadiene, ethylene-vinyl acetate copolymers, polyamide, and polysulfone; and combinations thereof. Papers may include impregnated paper, coated paper, wood free paper, Kraft paper, Japanese paper, glassine paper, synthetic paper, and combinations thereof. Depending on the size of the patches, the size of the backing may vary, and in some instances sized to cover the entire application site on the subject. As such, the Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 backing layer may have a length ranging from 2 to 100 cm, such as 4 to 60 cm and a width ranging from 2 to 100 cm, such as 4 to 60 cm. In certain instances, the backing layer may insoluble in water. By insoluble in water is meant that that the backing layer may be immersed in water for a period of 1 day or longer, such as 1 week or longer, including 1 month or longer, and exhibit little if any dissolution, e.g., no observable dissolution. In certain embodiments, patches of interest include a pressure sensitive adhesive, such as for maintaining the patch in contact with the skin surface of a subject for an extended period of time. Pressure sensitive adhesives may include, but are not limited to, poly-isobutene adhesives, poly-isobutylene adhesives, poly- isobutene/polyisobutylene adhesive mixtures, carboxylated polymers, acrylic or acrylate copolymers, such as carboxylated acrylate copolymers. Where the pressure sensitive adhesive includes polybutene, the polybutene may be saturated polybutene. Alternatively, the polybutene may be unsaturated polybutene. Still further, the polybutene may be a mixture or combination of saturated polybutene and unsaturated polybutene. In some embodiments, the pressure sensitive adhesive may include a composition that is, or is substantially the same as, the composition of Indopol® L-2, Indopol® L-3, Indopol® L-6, Indopol® L-8, Indopol® L-14, Indopol® H-7, Indopol® H-8, Indopol® H-15, Indopol® H-25, Indopol® H-35, Indopol® H-50, Indopol® H-100, Indopol® H-300, Indopol® H-1200, Indopol® H-1500, Indopol® H-1900, Indopol® H-2100, Indopol® H-6000, Indopol® H-18000, Panalane® L-14E, Panalane® H-300E and combinations thereof. In certain embodiments, the polybutene pressure-sensitive adhesive is Indopol® H-1900. In other embodiments, the polybutene pressure-sensitive adhesive is Panalane® H-300E. Acrylate copolymers of interest include copolymers of various monomers, such as “soft” monomers, “hard” monomers or “functional” monomers. The acrylate copolymers can be composed of a copolymer including bipolymer (i.e., made with two monomers), a terpolymer (i.e., made with three monomers), or a tetrapolymer (i.e., made with four monomers), or copolymers having greater numbers of monomers. The acrylate copolymers may be crosslinked or non-crosslinked. The polymers can be cross-linked by known methods to provide the desired polymers. The monomers from of the acrylate copolymers may include at least two or more exemplary components selected from the Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 group including acrylic acids, alkyl acrylates, methacrylates, copolymerizable secondary monomers or monomers with functional groups. Monomers (“soft” and “hard” monomers) may be methoxyethyl acrylate, ethyl acrylate, butyl acrylate, butyl methacrylate, hexyl acrylate, hexyl methacrylate, 2-ethylbutyl acrylate, 2-ethylbutyl methacrylate, isooctyl acrylate, isooctyl methacrylate, 2-ethylhexyl acrylate, 2-ethylhexyl methacrylate, decyl acrylate, decyl methacrylate, dodecyl acrylate, dodecyl methacrylate, tridecyl acrylate, tridecyl methacrylate, acrylonitrile, methoxyethyl acrylate, methoxyethyl methacrylate, and the like. Additional examples of acrylic adhesive monomers are described in Satas, "Acrylic Adhesives," Handbook of Pressure-Sensitive Adhesive Technology, 2nd ed., pp.396-456 (D. Satas, ed.), Van Nostrand Reinhold, New York (1989), the disclosure of which is herein incorporated by reference. In some embodiments, the pressure sensitive adhesive is an acrylate-vinyl acetate copolymer. In some embodiments, the pressure sensitive adhesive may include a composition that is, or is substantially the same as, the composition of Duro-Tak® 87-9301, Duro-Tak® 87- 200A, Duro-Tak®87-2353, Duro-Tak®87-2100, Duro-Tak®87-2051, Duro-Tak®87-2052, Duro-Tak®87-2194, Duro-Tak®87-2677, Duro-Tak®87-201A, Duro-Tak®87-2979, Duro- Tak®87-2510, Duro-Tak®87-2516, Duro-Tak®87-387, Duro-Tak®87-4287, Duro- Tak®87-2287,and Duro-Tak®87-2074 and combinations thereof. The term “substantially the same” as used herein refers to a composition that is an acrylate-vinyl acetate copolymer in an organic solvent solution. In certain embodiments, the acrylic pressure-sensitive adhesive is Duro-Tak® 87-2054. METHODS FOR APPLYING A POLYMERIC STRUCTURE HAVING A PLURALITY OF POLYMERIC MICRONEEDLES Aspects of the present disclosure also include methods for applying the polymeric structures (as described above) having a plurality of polymeric microneedles to a skin surface of a subject. In some embodiments, applying the polymeric structures described herein provide for transdermal administration of one or more active agent compounds. In some embodiments, the polymeric structures may be employed to collect a biological fluid sample by applying the patch to a skin surface of the subject. Transdermal refers to the route of administration where an active agent (i.e., drug) is delivered across the skin (e.g., topical administration) or mucous membrane or where a Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 biological sample such as interstitial fluid is collected from the subject. As such, the polymeric structures as described herein are configured to deliver an active agent compound or collect a biological sample from the subject through one or more of the subcutis, dermis and epidermis, including the stratum corneum, stratum germinativum, stratum spinosum and stratum basale. Accordingly, the polymeric structures containing the plurality of polymeric microneedles may be applied at any convenient location, such as for example, the arms, legs, buttocks, abdomen, back, neck, scrotum, vagina, face, behind the ear, buccally as well as sublingually. In describing methods of the present invention, the term “subject” is meant the person or organism to which the patch is applied and maintained in contact. As such, subjects of the invention may include but are not limited to mammals, e.g., humans and other primates, such as chimpanzees and other apes and monkey species; and the like, where in certain embodiments the subject are humans. The term subject is also meant to include a person or organism of any age, weight or other physical characteristic, where the subjects may be an adult, a child, an infant or a newborn. In some embodiments, methods include extended delivery of an active agent compound to the subject. By “extended delivery” is meant that the polymeric structures are configured to provide for administration of the active agent compound over an extended period of time, such as over the course of hours, days and including weeks, including 1 hour or longer, such as 2 hours or longer, such as 4 hours or longer, such as 8 hours or longer, such as 12 hours or longer, such as 24 hours or longer, such as 48 hours or longer, such as 72 hours or longer, such as 96 hours or longer, such as 120 hours or longer, such as 144 hours or longer and including 168 hours or longer. In some embodiments, the polymeric structures are configured for sustained release of the active agent compound and includes multi-day delivery of a therapeutically effective amount of the active agent compound. By multi-day delivery is meant that the polymeric microneedles of the polymeric structures are formulated to provide a therapeutically effective amount of the active agent compound to a subject when applied to the skin of a subject for a period of time that is 1 day or longer, such as 2 days or longer, such as 4 days or longer, such as 7 days or longer, such as 14 days and including 30 days or longer. In certain embodiments, the polymeric structures provide a therapeutically effective amount of the active agent compound to a subject for a period of 10 days or Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 longer. For multi-day administration, an upper limit period of time is, in some instances, 30 days or shorter, such as 28 days or shorter, such as 21 days or shorter, such as 14 days or shorter, such as 7 days or shorter and including 3 days or shorter. In certain embodiments, multi-day delivery ranges such as from 2 days to 30 days, such as from 3 days to 28 days, such as from 4 days to 21 days, such as from 5 days to 14 days and including from 6 days to 10 days. In certain embodiments, protocols may include multiple dosage intervals. By “multiple dosage intervals” is meant more than one polymeric structure is applied and maintained in contact with the subject in a sequential manner. As such, a polymeric structure is removed from contact with the subject and a new patch is reapplied to the subject. In practicing methods of the invention, treatment regimens may include two or more dosage intervals, such as three or more dosage intervals, such as four or more dosage intervals, such as five or more dosage intervals, including ten or more dosage intervals. The duration between dosage intervals in a multiple dosage interval treatment protocol may vary, depending on the physiology of the subject or by the treatment protocol as determined by a health care professional. For example, the duration between dosage intervals in a multiple dosage treatment protocol may be predetermined and follow at regular intervals. As such, the time between dosage intervals may vary and may be 1 day or longer, such as 2 days or longer, such as 3 days or longer, such as 4 days or longer, such as 5 days or longer, such as 6 days or longer, such as 7 days or longer, such as 10 days or longer, including 30 days or longer. An upper limit period of time between dosage intervals is, in some instances, 30 days or shorter, such as 28 days or shorter, such as 21 days or shorter, such as 14 days or shorter, such as 7 days or shorter and including 3 days or shorter. In certain embodiments, the time between dosage intervals ranges such as from 2 days to 30 days, such as from 3 days to 28 days, such as from 4 days to 21 days, such as from 5 days to 14 days and including from 6 days to 10 days. In certain embodiments, methods further include the step of removing the polymeric structure from contact with the subject at the conclusion of a dosage interval. For example, the polymeric structure may be removed from contact with the subject after maintaining the polymeric structure in contact with the subject for 0.5 hours or more, Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 such as 1 hour or more, such as 2 hours or more, such as 4 hours or more, such as 8 hours or more, such as 12 hours or more, such as 24 hours or more, such as 36 hours or more, such as 48 hours or more, such as 60 hours or more, such as 72 hours or more, such as 96 hours or more, such as 120 hours or more, including 144 hours or more, and including 168 hours or more. An upper limit for the amount of time the polymeric structure is maintained in contact with a subject before removal is, in some instances, 168 hours or shorter, such as 144 hours or shorter, such as 120 hours or shorter, such as 96 hours or shorter, such as 72 hours or shorter, such as 48 hours or shorter, such as 24 hours or shorter, such as 12 hours or shorter, such as 8 hours or shorter, such as 4 hours or shorter and including 2 hours or shorter. The location on the subject for reapplying subsequent polymeric structures in multiple dosage treatment regimens may be the same or different from the location on the subject where the previous polymeric structure was removed. For example, if a first polymeric structure is applied and maintained on the leg of the subject, one or more subsequent polymeric structures may be reapplied to the same position on the leg of the subject. On the other hand, if a first polymeric structure was applied and maintained on the leg of the subject, one or more subsequent polymeric structures may be reapplied to a different position, such as the abdomen or back of the subject. Subsequent dosages applied in multiple dosage interval regimens may have the same or different active agent compound. In certain instances, a subsequent dosage interval in a treatment regimen may contain a higher or lower concentration of active agent compound than the previous dosage interval. For example, the concentration of the active agent compound may be increased in subsequent dosage intervals by 10% or greater, such as 20% or greater, such as 50% or greater, such as 75% or greater, such as 90% or greater and including 100% or greater. An upper limit for the increase in concentration of active agent compound in subsequent dosage intervals is, in some instances, 10-fold or less, such as 5-fold or less, such as 2-fold or less, such as 1-fold or less, such as 0.5-fold or less and including 0.25-fold or less. On the other hand, the amount of active agent compound may be decreased in subsequent dosage intervals, such as by 10% or greater, such as 20% or greater, such as 50% or greater, such as 75% or greater, such as 90% or greater and including 100% or greater. An upper limit for the decrease in amount of the active agent compound in Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 subsequent dosage intervals is, in some instances, 10-fold or less, such as 5-fold or less, such as 2-fold or less, such as 1-fold or less, such as 0.5-fold or less and including 0.25-fold or less. In other instances, a subsequent dosage interval may contain a different active agent compound than the previous dosage interval. In some embodiments, methods include applying one or more polymeric structures to a skin surface of a subject in a manner to collect a biological fluid sample from the subject. The biological fluid sample may be collected into the polymeric microneedles of the polymeric structures by any convenient protocol, such as for example by capillary action. In embodiments, the biological fluid sample is collected from one or more of the subcutis, dermis and epidermis, including the stratum corneum, stratum germinativum, stratum spinosum and stratum basale of the subject. In certain instances, the biological fluid sample is interstitial fluid. In certain instances, the biological fluid sample is dermal fluid. In certain instances, the biological fluid sample is blood. In some embodiments, methods include collecting a biological fluid sample from the subject (e.g., interstitial fluid, dermal fluid) for detecting an analyte present in the biological sample, such as for detecting glucose. In some embodiments, the polymeric structure is maintained in contact with the subject for an extended period of time sufficient to collect biological fluid sample from the subject, such as over the course of hours, days and including weeks, including 1 hour or longer, such as 2 hours or longer, such as 4 hours or longer, such as 8 hours or longer, such as 12 hours or longer, such as 24 hours or longer, such as 48 hours or longer, such as 72 hours or longer, such as 96 hours or longer, such as 120 hours or longer, such as 144 hours or longer and including 168 hours or longer. In some embodiments, the polymeric microneedles are configured for multi-day collection of the biological fluid sample. By multi-day collection is meant that the polymeric microneedles of the polymeric structures are configured to continuously or in predetermined intervals collect biological sample from a subject when applied to the skin of a subject for a period of time that is 1 day or longer, such as 2 days or longer, such as 4 days or longer, such as 7 days or longer, such as 14 days and including 30 days or longer. In certain embodiments, patches are maintained in contact with the subject for a period of 10 days or longer. For multi-day collection of biological samples, an upper limit period of time is, in some instances, 30 days or shorter, such as 28 days or shorter, such as 21 days or Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 shorter, such as 14 days or shorter, such as 7 days or shorter and including 3 days or shorter. In certain embodiments, multi-day transdermal delivery ranges such as from 2 days to 30 days, such as from 3 days to 28 days, such as from 4 days to 21 days, such as from 5 days to 14 days and including from 6 days to 10 days. In certain embodiments, protocols may include multiple collection intervals. By “multiple collection intervals” is meant more than one polymeric structure is applied and maintained in contact with the subject in a sequential manner. As such, a patch is removed from contact with the subject and a new polymeric structure is reapplied to the subject. In practicing methods of the invention, treatment regimens may include two or more collection intervals, such as three or more collection intervals, such as four or more collection intervals, such as five or more collection intervals, including ten or more collection intervals. The duration between collection intervals in a multiple collection interval treatment protocol may vary, depending on the physiology of the subject or by the treatment protocol as determined by a health care professional. For example, the duration between collection intervals in a multiple collection protocol may be predetermined and follow at regular intervals. As such, the time between collection intervals may vary and may be 1 day or longer, such as 2 days or longer, such as 3 days or longer, such as 4 days or longer, such as 5 days or longer, such as 6 days or longer, such as 7 days or longer, such as 10 days or longer, including 30 days or longer. An upper limit period of time between collection intervals is, in some instances, 30 days or shorter, such as 28 days or shorter, such as 21 days or shorter, such as 14 days or shorter, such as 7 days or shorter and including 3 days or shorter. In certain embodiments, the time between collection intervals ranges such as from 2 days to 30 days, such as from 3 days to 28 days, such as from 4 days to 21 days, such as from 5 days to 14 days and including from 6 days to 10 days. In certain embodiments, methods further include the step of removing the polymeric structure from contact with the subject at the conclusion of a collection interval. For example, the polymeric structure may be removed from contact with the subject after maintaining the patch in contact with the subject for 0.5 hours or more, such as 1 hour or more, such as 2 hours or more, such as 4 hours or more, such as 8 hours or more, such as 12 hours or more, such as 24 hours or more, such as 36 hours or Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 more, such as 48 hours or more, such as 60 hours or more, such as 72 hours or more, such as 96 hours or more, such as 120 hours or more, including 144 hours or more, and including 168 hours or more. An upper limit for the amount of time the polymeric structure is maintained in contact with a subject before removal is, in some instances, 168 hours or shorter, such as 144 hours or shorter, such as 120 hours or shorter, such as 96 hours or shorter, such as 72 hours or shorter, such as 48 hours or shorter, such as 24 hours or shorter, such as 12 hours or shorter, such as 8 hours or shorter, such as 4 hours or shorter and including 2 hours or shorter. Polymeric structures having a plurality of polymeric microneedles according to embodiments of the invention are non-irritable to the skin of the subject at the site of application. Irritation of the skin is referred to herein in its general sense to refer to adverse effects, discoloration or damage to the skin, such as for example, redness, pain, swelling or dryness. As such, in practicing methods with the subject polymeric structures the quality of the skin remains normal and is consistent throughout the entire dosage or collection interval. In some embodiments, skin irritation is evaluated to determine the quality and color of the skin at the application site and to determine whether any damage, pain, swelling or dryness has resulted from maintaining the polymeric structure in contact with the subject. The skin may be evaluated for irritation by any convenient protocol, such as for example using the Draize scale, as disclosed in Draize, J. H., Appraisal of the Safety of Chemicals in Foods, Drugs and Cosmetics, pp.46-49, The Association of Food and Drug Officials of the United States: Austin, Texas, the disclosure of which is herein incorporated by reference. In particular, the skin may be evaluated at the patch application site for erythema or edema. For example, grades for erythema and edema may be assigned based on visual observation or palpation: Erythema: 0=no visible redness; 1=very slight redness (just perceptible); 2=slight but defined redness; 3=moderately intense redness; 4=severe erythema (dark red discoloration of the skin) 5 = eschar formation Edema: 0=no visible reactions or swelling; 1=very mild edema (just perceptible swelling); 2=mild edema (corners of area are well Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 defined due to swelling); 3=moderate edema (up to 1 mm swelling); 4=severe edema (more than 1 mm swelling). The site of application may be evaluated for skin irritation at any time during the subject methods. In some instances, the skin is evaluated for irritation while maintaining the polymeric structure in contact with the subject by observing or palpating the skin at regular intervals, e.g., every 0.25 hours, every 0.5 hours, every 1 hour, every 2 hours, every 4 hours, every 12 hours, every 24 hours, including every 72 hours, or some other interval. For instance, the site of application may be evaluated for skin irritation while maintaining the polymeric structure in contact with the subject, such as 15 minutes after applying the polymeric structure to the subject, 30 minutes after applying the polymeric structure, 1 hour after applying the transdermal delivery device, 2 hours after applying the patch, 4 hours after applying the polymeric structure, 8 hours after applying the polymeric structure, 12 hours after applying the polymeric structure, 24 hours after applying the polymeric structure, 48 hours after applying the polymeric structure, 72 hours after applying the polymeric structure, 76 hours after applying the polymeric structure, 80 hours after applying the polymeric structure, 84 hours after applying the polymeric structure, 96 hours after applying the polymeric structure, 120 hours after applying the polymeric structure, including 168 hours after applying the polymeric structure. M^{ETHODS FOR} M^AKING P^OLYMERIC S^TRUCTURES H^{AVING A} P^OLYMERIC M^ICRONEEDLE Aspects of the disclosure also include methods for making a polymeric structure having one or more polymeric microneedles as described herein. Methods according to certain embodiments is a high resolution continuous additive processing method that includes irradiating a polymerizable composition positioned between a build elevator and a build surface to generate a polymerizable composition having a first polymerized region of the polymerizable composition in contact with the build elevator and a first non- polymerized region of the polymerizable composition in contact with the build surface; displacing the build elevator away from the build surface; irradiating the first non- polymerized region of the polymerizable composition to generate a second polymerized region of the polymerizable composition in contact with the first polymerized region and a second non-polymerized region in contact with the build surface and repeating in a Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 manner sufficient to generate the polymeric structure. These steps are repeated in a manner sufficient to generate a polymeric structure which exhibits a macrostructural change in response to an applied stimulus. For example, the steps may be repeated 2 or more times, such as 3 or more times, such as 4 or more times, such as 5 or more times, such as 10 or more times, such as 20 or more times, such as 30 or more times, such as 40 or more times, such as 50 or more times, such as 100 or more times, such as 250 or more times, such as 500 or more times and including 1000 or more times. In some embodiments, the polymerizable composition is irradiated with a light beam generator component of a micro-digital light projection system. In some instances, the light source is a broadband light source that emits light having wavelengths from 400 nm to 1000 nm. In some instances, the broadband light source is a halogen lamp, deuterium arc lamp, xenon arc lamp, stabilized fiber-coupled broadband light source, a broadband LED with continuous spectrum, superluminescent emitting diode, semiconductor light emitting diode, wide spectrum LED white light source, a multi-LED integrated white light source, among other broadband light sources or any combination thereof. In some instances, the light source is a narrow band light source emitting a particular wavelength or a narrow range of wavelengths. In some instances, the narrow band light sources emit light having a narrow range of wavelengths, such as for example, 50 nm or less, such as 40 nm or less, such as 30 nm or less, such as 25 nm or less, such as 20 nm or less, such as 15 nm or less, such as 10 nm or less, such as 5 nm or less, such as 2 nm or less and including light sources which emit a specific wavelength of light. In some instances, the polymerizable composition is irradiated with a narrow band light source such as a narrow wavelength LED, laser diode or a broadband light source coupled to one or more optical bandpass filters, diffraction gratings, monochromators or any combination thereof. In certain embodiments, the light source is a stroboscopic light source and the polymerizable composition is illuminated with periodic flashes of light, such as where the polymerizable composition is irradiated at a frequency of 0.01 kHz or greater, such as 0.05 kHz or greater, such as 0.1 kHz or greater, such as 0.5 kHz or greater, such as 1 kHz or greater, such as 2.5 kHz or greater, such as 5 kHz or greater, such as 10 kHz or greater, such as 25 kHz or greater, such as 50 kHz or greater and including 100 kHz or Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 greater. In certain instances, the polymerizable composition is irradiated with a laser, such as pulsed laser or a continuous wave laser. In some embodiments, the polymerizable composition is in contact with the build elevator and the build surface. In some instances, methods include irradiating the polymerizable composition for 1 second or longer to bond the first polymerized region of the polymerizable composition to the build elevator, such as from 5 seconds longer, such as for 10 seconds or longer, such as for 20 seconds or longer, such as for 30 seconds or longer, such as for 1 minute or longer, such as for 5 minutes or longer and including for 10 minutes or longer. In some embodiments, the build elevator is displaced away from the build surface after the first polymerized region of the polymerizable composition is bonded to the build elevator. In some instances, the build elevator is displaced in increments of 0.001 µm or more, such as 0.005 µm or more, such as 0.01 µm or more, such as 0.05 µm or more, such as 0.1 µm or more, such as 0.5 µm or more, such as 1 µm or more, such as 2 µm or more, such as 3 µm or more, such as 4 µm or more, such as 5 µm or more and including in increments of 10 µm or more. In certain instances, the build elevator is displaced in increments of from 0.001 µm to 20 µm, such as from 0.005 µm to 19 µm, such as from 0.01 µm to 18 µm, such as from 0.05 µm to 17 µm, such as from 0.1 µm to 16 µm, such as from 0.2 µm to 17 µm, such as from 0.3 µm to 16 µm, such as from 0.4 µm to 15 µm, such as from 0.5 µm to 14 µm, such as from 0.6 µm to 13 µm, such as from 0.7 µm to 12 µm, such as from 0.8 µm to 11 µm and including from 0.9 µm to 10 µm. In certain instances, polymerizable composition is added to the build surface after each displacement of the build elevator away from the build surface. In some instances, the polymerizable composition is continuously added to the build surface. In other instances, the polymerizable composition is added to the build surface in discreet intervals each having a predetermined amount. In some embodiments, the polymerizable composition is selected from polycaprolactone, polyglycolic acid, polylactic acid, polylactic-co-glycolic acid, polyethylene glycol, thiol-enes, anhydrides, polyacrylic acid, poly methylmethacrylate, polyvinyl alcohol, polyvinylpyrrolidone, vinyl carbonates, vinyl esters, acrylamides, hyaluronic acid, chitosan, collagen, gelatin, Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 carboxymethylcellulose, and blends or copolymers thereof. In certain embodiments, polymeric microneedles are formed from polyethylene glycol dimethacrylate (PEGDMA). In some embodiments, the polymerizable composition is irradiated through build surface. In some instances, the polymerizable composition is irradiated in the presence of a polymerization inhibitor. In certain embodiments, the polymerizable composition is continuously polymerized while displacing the build elevator away from the build surface. In certain cases, the polymerization inhibitor is oxygen and the build surface is permeable to oxygen. In certain instances, polymerizing the polymerizable composition in the presence of a polymerization inhibitor such as oxygen enables continuous (i.e., not layer-by-layer) generation the lattice microstructure with a liquid “dead zone” at the interface between the build surface and the building polymeric microneedle. In some instances, the dead zone is generated because oxygen acts as a polymerization inhibitor, passing through the oxygen-permeable build surface. Photopolymerization cannot occur in the oxygen containing “dead zone” region such that this region remains fluid, and the polymerized component in contact with the build surface so that the building lattice microstructure does not physically attach to the build surface. In some embodiments, the polymeric structures described are polymerized using high resolution continuous liquid interface production such as described in International Patent Publication No. WO 2023/049267, the disclosure of which is herein incorporated by reference. In certain embodiments, the polymerizable composition is polymerized using a liquid interface polymerization module that is a continuous liquid interface production (CLIP) system such as that described in International Patent Publication No. WO 2014/126837; U.S. Patent Publication Nos.2018/0064920; 2017/0095972; 2021/0246252 and U.S. Patent Publication Nos.10,155,882; 10,792,857, the disclosures of which are herein incorporated by reference. In certain embodiments, the polymeric structure is generated by injection continuous liquid interface production by conveying the polymerizable composition through a conduit into a space between a build elevator and a build surface of a liquid interface production module, such as described in International Patent Application No. PCT/US2023/15406 filed on March 16, 2023, the disclosure of which is herein incorporated by reference. In some embodiments, methods include irradiating the polymerizable composition with a micro-digital light projection system as described in detail above. In Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 some instances, methods include determining a focal plane on the build surface using the micro-digital light projection system. In some embodiments, determining the focal plane on the build surface includes irradiating the build surface with a stroboscopic light source through the tube lens and displacing the build surface until the light is focused on the build surface through the tube lens. In certain embodiments, methods for determining the focal plane on the build surface includes irradiating build surface with the stroboscopic light source with periodic flashes of light. For example, the frequency of each light pulse may be 0.0001 kHz or greater, such as 0.0005 kHz or greater, such as 0.001 kHz or greater, such as 0.005 kHz or greater, such as 0.01 kHz or greater, such as 0.05 kHz or greater, such as 0.1 kHz or greater, such as 0.5 kHz or greater, such as 1 kHz or greater, such as 2.5 kHz or greater, such as 5 kHz or greater, such as 10 kHz or greater, such as 25 kHz or greater, such as 50 kHz or greater and including 100 kHz or greater. In certain instances, the frequency of pulsed irradiation by the light source ranges from 0.00001 kHz to 1000 kHz, such as from 0.00005 kHz to 900 kHz, such as from 0.0001 kHz to 800 kHz, such as from 0.0005 kHz to 700 kHz, such as from 0.001 kHz to 600 kHz, such as from 0.005 kHz to 500 kHz, such as from 0.01 kHz to 400 kHz, such as from 0.05 kHz to 300 kHz, such as from 0.1 kHz to 200 kHz and including from 1 kHz to 100 kHz. The duration of light irradiation for each light pulse (i.e., pulse width) may vary and may be 0.000001 ms or more, such as 0.000005 ms or more, such as 0.00001 ms or more, such as 0.00005 ms or more, such as 0.0001 ms or more, such as 0.0005 ms or more, such as 0.001 ms or more, such as 0.005 ms or more, such as 0.01 ms or more, such as 0.05 ms or more, such as 0.1 ms or more, such as 0.5 ms or more, such as 1 ms or more, such as 2 ms or more, such as 3 ms or more, such as 4 ms or more, such as 5 ms or more, such as 10 ms or more, such as 25 ms or more, such as 50 ms or more, such as 100 ms or more and including 500 ms or more. For example, the duration of light irradiation may range from 0.000001 ms to 1000 ms, such as from 0.000005 ms to 950 ms, such as from 0.00001 ms to 900 ms, such as from 0.00005 ms to 850 ms, such as from 0.0001 ms to 800 ms, such as from 0.0005 ms to 750 ms, such as from 0.001 ms to 700 ms, such as from 0.005 ms to 650 ms, such as from 0.01 ms to 600 ms, such as from 0.05 ms to 550 ms, such as from 0.1 ms to 500 ms, such as from 0.5 ms to 450 ms, such as from 1 ms to 400 ms, such as from 5 ms to 350 ms and including from 10 ms to 300 ms. In some instances, methods include irradiating the build Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 surface with a plane of light having a projected image pattern with the stroboscopic light source. In some instances, determining the focal plane on the build surface includes adjusting the focus of the tube lens. In some instances, the focal point of the tube lens is increased to adjust the focus onto the build surface. For example, the focal point may be increased by 1 µm or more, such as by 5 µm or more, such as by 10 µm or more, such as by 50 µm or more, such as by 100 µm or more, such as by 500 µm or more, such as by 1 mm or more, such as by 5 mm or more, such as by 10 mm or more, such as by 50 mm or more and including by 100 mm or more. In some instances, the focal point of the tube lens is decreased to adjust the focus onto the build surface. For example, the focal point may be decreased by 1 µm or more, such as by 5 µm or more, such as by 10 µm or more, such as by 50 µm or more, such as by 100 µm or more, such as by 500 µm or more, such as by 1 mm or more, such as by 5 mm or more, such as by 10 mm or more, such as by 50 mm or more and including by 100 mm or more. In some embodiments, methods include displacing the build surface until the projected image pattern is in focus with the build surface. The build surface and build elevator may be displaced using any convenient displacement protocol, such as manually (i.e., movement of the build surface or build elevator directly by hand), with assistance by a mechanical device or by a motor actuated displacement device. For example, in some embodiments the build surface or build elevator is moved with a mechanically actuated translation stage, mechanical leadscrew assembly, mechanical slide device, mechanical lateral motion device, mechanically operated geared translation device. In other embodiments, the build surface or build elevator is moved with a motor actuated translation stage, leadscrew translation assembly, geared translation device, such as those employing a stepper motor, servo motor, brushless electric motor, brushed DC motor, micro-step drive motor, high resolution stepper motor, among other types of motors. In some instances, the build surface is displaced by 1 µm or more, such as by 5 µm or more, such as by 10 µm or more, such as by 50 µm or more, such as by 100 µm or more and including by 500 µm or more. In certain embodiments, the build surface is displaced by 400 µm or less, such as 350 µm or less, such as by 300 µm or less, such as by 250 µm or less, such as by 200 µm or less, such as by 150 µm or less, such as by 100 µm or less and including by 50 µm or less. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 In some instances, methods include generating an image stack having a plurality of the projected image patterns. The image stack may include 2 or more projected image patterns, such as 3 or more, such as 4 or more, such as 5 or more, such as 10 or more and including 25 or more projected image patterns. In certain instances, methods include determining the focal plane of the build surface based on the generated image stack. In embodiments, methods as described here for generating polymeric microstructures (e.g., polymeric microneedles) having a lattice microstructure provide for a resolution of 10 µm or less, such as 5 µm or less. In certain embodiments, the subject methods provide for a resolution of from 1.0 µm to 4 µm, such as from 1.5 µm to 3.8 µm. As described above, in some instances the polymeric microneedles of the polymeric structure include an active agent compound. Methods according to certain embodiments include preparing a polymeric structure where the one or more polymeric microneedles have an active agent compound. Methods in some instances include coating the active agent compound onto a surface of the polymeric microneedle. In some instances, the active agent compound is coated onto a surface of the polymeric microneedle as a fluidic composition. In these embodiments, the fluidic composition may be applied to the surface of the polymeric microneedle by for example, dip-coating or spray coating the active agent composition. In some embodiments, methods include coating a surface of the polymeric microneedle with a solid active agent compound such as by dry-casting a powder containing the active agent compound. In some instances, methods include coating 5% or more of the surface of the polymeric microneedle with the active agent compound, such as 10% or more, such as 15% or more, such as 20% or more, such as 25% or more, such as 50% or more, such as 75% or more, such as 90% or more and including coating 95% or more of the surface of the polymeric microneedle. In certain instances, the entire surface of the polymeric microneedle is coated with the active agent compound. In some instances, methods include coating the active agent compound onto a tip section of the polymeric microneedle. In some instances, methods include coating the active agent onto a surface of the body section of the polymeric microneedle. In some instances, methods include coating the active agent onto a surface of a base section of the polymeric microneedle. In certain instances, the lattice microstructure component of the polymeric microneedle is coated with the active agent compound. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 Depending on the dosage amount of the active agent compound desired, the amount of active agent compound coated onto the surface may vary, such as coating 0.001 µg or more onto a surface of the polymeric microneedle, such as 0.005 µg or more, such as 0.01 µg or more, such as 0.05 µg or more, such as 0.1 µg or more, such as 0.5 µg or more, such as 1 µg or more, such as 5 µg or more, such as 25 µg or more, such as 50 µg or more, such as 100 µg or more and including coating 500 µg or more of the active agent compound onto the surface of the polymeric microneedle. In some embodiments, the active agent compound is incorporated into an interior space of the lattice microstructure of the polymeric microneedle. In some instances, methods include microfluidic injection filling of the active agent compound into the lattice microstructure of the polymeric microneedles. In other instances, methods include contacting the lattice microstructure with a composition containing the active agent compound and incorporating the active agent by capillary action. In some embodiments, the polymeric microneedles are dipped into a composition containing the active agent compound and an amount of the active agent is incorporated into the void space of the lattice microstructure by capillary action. Depending on the density of the lattice cell units in the lattice microstructure, the polymeric microneedle may be contacted with (submerged within) the active agent composition for 0.01 minutes or more, such as for 0.05 minutes or more, such as for 0.1 minutes or more, such as for 0.5 minutes or more, such as from 1 minute or more, such as for 5 minutes or more, such as for 10 minutes or more, such as for 30 minutes or more, such as for 60 minutes or more and including for 6 hours or more to take up the active agent composition into the lattice microstructure. In some embodiments, methods include preparing polymeric microneedles where the lattice microstructure contains regions of increased concentration of the active agent compound, such as where the concentration of active agent compound in these regions increases by 1% or more across the longitudinal axis of the lattice microstructure, such as by 2% or more, such as by 3% or more, such as by 4% or more, such as by 5% or more, such as by 10% or more, such as by 20% or more, such as by 30% or more, such as by 40% or more and including by 50% or more. In some instances, the regions of increased concentrations of active agent are present at various increments across the longitudinal axis of the lattice microstructure. For example, the regions of increased active agent concentration may be present at increments of every 10 µm or more across Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 the longitudinal axis of the lattice microstructure, such as every 20 µm or more, such as every 30 µm or more, such as every 40 µm or more and including every 50 µm or more. In some embodiments, methods for preparing a polymeric microneedle containing an active agent compound include incorporating the active agent compound into the polymerizable composition, such that when the polymeric microneedle is formed from the polymerizable composition (e.g., by high resolution digital light projection- continuous liquid interface processing as described above) the active agent compound is present within the void space of the lattice microstructure. For example, the active agent composition may be present in the polymerizable composition at a concentration of 0.005 µg/µL or more, such as 0.01 µg/µL or more, such as 0.05 µg/µL or more, such as 0.1 µg/µL or more, such as 0.5 µg/µL or more, such as 1 µg/µL or more, such as 5 µg/µL or more, such as 25 µg/µL or more, such as 50 µg/µL or more, such as 100 µg/µL or more and including coating 500 µg/µL or more. In some instances, where the lattice microstructure has regions of increased concentration of active agent compound, methods include increasing the amount of active agent composition present in the source of the polymerizable composition while preparing the polymeric microneedle, such as by increasing the amount of active agent in the polymerizable composition by 1% or more, such as by 2% or more, such as by 5% or more, such as by 10% or more, such as by 25% or more, such as by 50% or more and including by 75% or more. K^ITS Kits for use in practicing certain methods described herein are also provided. In certain embodiments, the kits include one or more polymeric structures containing a plurality of polymeric microneedles as described above. In certain embodiments, the kits include an adhesive overlay, such as a backing layer having a pressure sensitive adhesive. In a given kit that includes two or more of the subject polymeric structures, the polymeric structures may be individually packaged or present within a common container. In certain embodiments, kits include an active agent compound for delivering to a subject, such as a small molecule active agent or an immunogenic active agent compound (e.g., a vaccine) as described above. In certain instances, the active agent compound may be pre-loaded into the polymeric microneedles of the polymeric structure device or may be present in a separate container in the kits. In some instances, the Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 active agent compound is pre-loaded into a reservoir component which can be coupled to the polymeric structure for delivering to a subject. In certain instances, kits include one or more microfluidics for conveying active agent to the polymeric structure or for drawing a biological fluid medium from the polymeric microstructure (e.g., to a reservoir component). In certain embodiments, the kits will further include instructions for practicing the subject methods or means for obtaining the same (e.g., a website URL directing the user to a webpage which provides the instructions), where these instructions may be printed on a substrate, where substrate may be one or more of: a package insert, the packaging, reagent containers and the like. Yet another form of these instructions is a computer readable medium, e.g., diskette, compact disk (CD), portable flash drive, USB storage, DVD, Blu-ray disk, etc.), and the like, on which the information has been recorded. Yet another form of these instructions that may be present is a website address which may be used via the internet to access the information at a removed site. Notwithstanding the appended claims, the disclosure is also defined by the following clauses: 1. A polymeric structure comprising one or more polymeric microneedles, wherein each polymeric microneedle comprises a microstructural component configured to facilitate one or more of: insertion of the polymeric microneedle into a skin surface of a subject; retention of the polymeric microneedle in the skin of the subject; creating a seal when the polymeric microneedle is inserted into the skin of the subject; and delivery of an active agent to a subject through the polymeric microneedle. 2. The polymeric structure according to clause 1, wherein each polymeric microneedle comprises: a tip section; a body section; and a base section. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 3. The polymeric structure according to clause 2, wherein one or more of the polymeric microneedles comprises a body section having a width that is greater than the width of the base section. 4. The polymeric structure according to any one of clauses 2-3, wherein the width of the body section is 25% greater or more than the width of the base section. 5. The polymeric structure according to any one of clauses 2-4, wherein the base section of each polymeric microneedle has a circular cross-section. 6. The polymeric structure according to any one of clauses 2-5, wherein one or more of the polymeric microneedles is tear-drop shaped. 7. The polymeric structure according to clause 2, wherein one or more of the polymeric microneedles comprises a base section having a width that varies along a longitudinal axis of the base section. 8. The polymeric structure according to clause 7, wherein the base section comprises: a first end having a first width; a second end having a second width; and a middle section between the first end and the second end having a third width. 9. The polymeric structure according to clause 8, wherein the middle section has a width which is less than width of the first end and the width of the second end. 10. The polymeric structure according to clause 8, wherein the first width, the second width and the third width are different from each other. 11. The polymeric structure according to any one of clauses 8-10, wherein: the first width is from 25 µm to 500 µm; the second width is from 25 µm to 500 µm; and the third width is from 1 µm to 100 µm. 12. The polymeric structure according to any one of clauses 7-11, wherein one or more of the polymeric microneedles has an arrowhead shape. 13. The polymeric structure according to any one of clauses 1-2, wherein one or more of the polymeric microneedles comprises a square pyramidal or conical projection shape. 14. The polymeric structure according to any one of clauses 1-13, wherein one or more of the polymeric microneedles comprises a lattice microstructure. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 15. The polymeric structure according to clause 14, wherein the lattice microstructure comprises a plurality of struts. 16. The polymeric structure according to clause 15, wherein one or more of the polymeric microneedles comprises a gradient in the number of struts such that the density of struts increases across a longitudinal axis of the microneedle. 17. The polymeric structure according to any one of clauses 15-16, wherein the struts have a thickness of from 25 µm to 150 µm. 18. The polymeric structure according to any one of clauses 15-17, wherein one or more of the polymeric microneedles comprises a gradient in the thickness of the struts such that the thickness of the struts increases across a longitudinal axis of the microneedle. 19. The polymeric structure according to clause 18, wherein the thickness of the struts increases from the tip section to the base section of the polymeric microneedle. 20. The polymeric structure according to any one of clauses 2-19, wherein one or more of the polymeric microneedles further comprises a pillar in contact with the base section of the polymeric microneedle. 21. The polymeric structure according to clause 20, wherein the pillar comprises a solid structure. 22. The polymeric structure according to any one of clauses 2-21, wherein each of the tip section, the body section and the base section has the same cross-sectional shape. 23. The polymeric structure according to any one of clauses 2-21, wherein one or more of the tip section, the body section and the base section has a different cross- sectional shape. 24. The polymeric structure according to any one of clauses 22-23, wherein one or more of the tip section, the body section and the base section has a rigid cross cross- sectional shape. 25. The polymeric structure according to clause 24, wherein each of the tip section, the body section and the base section has a rigid cross cross-sectional shape. 26. The polymeric structure according to clause 24, wherein the body section and the base section have a rigid cross cross-sectional shape. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 27. The polymeric structure according to any one of clauses 22-23, wherein the tip section has a conical cross-sectional shape. 28. The polymeric structure according to any one of clauses 2-27, wherein one or more of the polymeric microneedles comprises a beveled tip section. 29. The polymeric structure according to clause 28, wherein the tip section of the polymeric microneedle comprises a bevel angle of from 3° to 45°. 30. The polymeric structure according to any one of clauses 1-29, wherein one or more of the polymeric microneedles is positioned at an angle of 5° to 60° with respect to the skin surface of the subject. 31. The polymeric structure according to any one of clauses 1-30, wherein one or more of the polymeric microneedles comprises a hollow internal space. 32. The polymeric structure according to clause 31, wherein one or more of the polymeric microneedles comprises: a tip section comprising a solid structure; a body section comprising a hollow structure; and a base section comprising a solid structure. 33. The polymeric structure according to clause 31, wherein one or more of the polymeric microneedles comprises: a tip section comprising a solid structure; a body section comprising a lattice structure; and a base section comprising a solid structure. 34. The polymeric structure according to clause 31, wherein one or more of the polymeric microneedles comprises: a tip section comprising a lattice structure; a body section comprising a hollow structure; and a base section comprising a solid structure. 35. The polymeric structure according to any one of clauses 31-34, wherein one or more of the polymeric microneedles comprises: a solid tip section; and a body section and a base section that comprises one or more microfluidic channels. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 36. The polymeric structure according to clause 35, wherein the body section comprises an outlet for one of more of the microfluidic channels. 37. The polymeric structure according to any one of clauses 31-34, wherein one or more of the polymeric microneedles comprises: a tip section that comprises a hollow structure; and a body section and a base section that comprises one or more microfluidic channels. 38. The polymeric structure according to clause 37, wherein the tip section comprises an outlet for one or more of the microfluidic channels. 39. The polymeric structure according to clause 37, wherein the body section comprises an outlet for one of more of the microfluidic channels. 40. The polymeric structure according to any one of clauses 1-39, wherein one or more of the polymeric microneedles are fenestrated. 41. The polymeric structure according to clause 40, wherein one or more of the tip section, the body section and the base section are fenestrated. 42. The polymeric structure according to clause 41, wherein the tip section is fenestrated. 43. The polymeric structure according to clause 41, wherein the body section is fenestrated. 44. The polymeric structure according to any one of clauses 2-43, wherein each polymeric microneedle has a tip section that comprises a length of from 25 µm to 500 µm. 45. The polymeric structure according to any one of clauses 2-44, wherein the tip section comprises a base width of 50 µm to 300 µm. 46. The polymeric structure according to any one of clauses 2-45, wherein each polymeric microneedle has a tip width of from 0.1 µm to 10 µm. 47. The polymeric structure according to any one of clauses 2-45, wherein each polymeric microneedle has a tip diameter of from 0.1 µm to 10 µm. 48. The polymeric structure according to any one of clauses 2-47, wherein each polymeric microneedle has a body section that comprises a length of from 50 µm to 1000 µm. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 49. The polymeric structure according to clause 48, wherein the body section comprises a width of 50 µm to 300 µm. 50. The polymeric structure according to any one of clauses 2-49, wherein each polymeric microneedle has a base section that comprises a length of from 25 µm to 500 µm. 51. The polymeric structure according to clause 50, wherein the base section comprises a base width of 50 µm to 300 µm. 52. The polymeric structure according to any one of clauses 1-51, wherein each polymeric microneedle has a volume of from 0.01 µL to 2 µL. 53. The polymeric structure according to any one of clauses 1-52, wherein the polymeric structure is formed from one or more polymerizable materials. 54. The polymeric structure according to any one of clauses 1-52, wherein the polymeric structure is formed from two or more different polymerizable materials. 55. The polymeric structure according to any one of clauses 53-54 , wherein each polymerizable material is selected from the group consisting of polycaprolactone, polyglycolic acid, polylactic acid, polylactic-co-glycolic acid, polyethylene glycol, polyethylene glycol dimethacrylate (PEGDMA), thiol-enes, anhydrides, polyacrylic acid, poly methylmethacrylate, trimethylolpropane triacrylate (TMPTA) monomer, polyvinyl alcohol, polyvinylpyrrolidone, vinyl carbonates, vinyl esters, acrylamides, hyaluronic acid, chitosan, collagen, gelatin, carboxymethylcellulose, and blends or copolymers thereof. 56. The polymeric structure according to any one of clauses 53-55, wherein the polymerizable material comprises carbon nanotubes. 57. The polymeric structure according to any one of clauses 1-56, wherein one or more of the polymeric microneedles is formed from a biodegradable polymerizable material. 58. The polymeric structure according to any one of clauses 1-57, wherein the polymeric microneedles are dissolvable in an aqueous medium. 59. The polymeric structure according to any one of clauses 1-58, wherein one or more of the polymeric microneedles further comprises an active agent compound. 60. The polymeric structure according to clause 59, wherein the active agent comprises a small molecule active agent compound. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 61. The polymeric structure according to clause 59, wherein the active agent comprises an immunogenic active agent compound. 62. The polymeric structure according to clause 61, wherein the active agent compound comprises a vaccine. 63. The polymeric structure according to any one of clauses 60-62, wherein the active agent compound is lyophilized. 64. The polymeric structure according to any one of clauses 60-63, wherein one or more of the polymeric microneedles comprises a hydrogel comprising the active agent compound. 65. The polymeric structure according to any one of clauses 60-63, wherein the active agent compound is an unreconstituted solid. 66. The polymeric structure according to any one of clauses 1-65, wherein the polymeric structure is in fluid communication with one or more microfluidic channels. 67. The polymeric structure according to clause 66, wherein the polymeric structure comprises a plurality of microfluidic channels. 68. The polymeric structure according to any one of clauses 66-67, wherein microfluidic channels are in fluid communication with a source of a fluidic medium. 69. The polymeric structure according to any one of clauses 66-68, wherein the microfluidic channels are in fluid communication with a reservoir. 70. The polymeric structure according to any one of clauses 66-69, wherein the polymeric structure is in fluidic communication with a pump component. 71. The polymeric structure according to any one of clauses 66-70, wherein the polymeric structure is configured to convey a fluidic medium from the microfluidic channels through the polymeric microneedles. 72. The polymeric structure according to any one of clauses 69-71, wherein each polymeric microneedle is in fluid communication with a different reservoir. 73. The polymeric structure according to any one of clauses 66-72, wherein the polymeric structure is configured to draw a fluidic medium through the polymeric microneedles into the microfluidic channels. 74. The polymeric structure according to any one of clauses 66-73, wherein the microfluidic channels comprise a geometric shape configured to control the conveyance rate of a fluidic medium therein. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 75. The polymeric structure according to any one of clauses 1-74, wherein the polymeric structure comprises a plurality of polymeric microneedles. 76. The polymeric structure according to clause 75, wherein the polymeric structure comprises an array of polymeric microneedles. 77. The polymeric structure according to clause 76, wherein the polymeric structure comprises an array of reservoirs. 78. The polymeric structure according to clause 77, wherein the array of reservoirs are in fluid communication through one or more conduits. 79. The polymeric structure according to any one of clauses 1-78, wherein the polymeric structure further comprises a connector configured to couple the polymeric structure to a fluid reservoir. 80. The polymeric structure according to clause 79, wherein the connector comprises a Luer-lock fitting. 81. A method comprising applying to a skin surface of a subject a polymeric structure comprising one or more polymeric microneedles, wherein each polymeric microneedle comprises a microstructural component configured to facilitate one or more of: insertion of the polymeric microneedle into a skin surface of a subject; retention of the polymeric microneedle in the skin of the subject; creating a seal when the polymeric microneedle is inserted into the skin of the subject; and delivery of an active agent to a subject through the polymeric microneedle. 82. The method according to clause 81, wherein the polymeric structure comprises a plurality of polymeric microneedles. 83. The method according to clause 82, wherein the polymeric structure comprises an array of polymeric microneedles. 84. The method according to any one of clauses 81-83, wherein the polymeric microneedles comprise an active agent compound and applying the polymeric structure to the skin surface of the subject is sufficient to deliver a therapeutically effective amount of the active agent compound to the subject. 85. The method according to clause 84, wherein the active agent compound comprises a small molecule active agent compound. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 86. The method according to clause 84, wherein the active agent compound comprises an immunogenic active agent compound. 87. The method according to clause 86, wherein the active agent compound comprises a vaccine. 88. The method according to any one of clauses 84-87, wherein the active agent compound is lyophilized. 89. The method according to any one of clauses 84-87, wherein the polymeric microneedles comprise a hydrogel comprising the active agent compound. 90. The polymeric structure according to any one of clauses 84-87, wherein the active agent compound is an unreconstituted solid. 91. The method according to any one of clauses 84-90, wherein the active agent compound is conveyed to the polymeric structure through a microfluidic channel in fluid communication with each polymeric microneedle. 92. The method according to clause 91, wherein the microfluidic channel is in fluid communication with a reservoir. 93. The method according to any one of clauses 91-92, wherein each polymeric microneedle is in fluid communication with a different reservoir. 94. The method according to any one of clauses 91-93, wherein the polymeric structure comprises an array of reservoirs. 95. The method according to clause 94, wherein the array of reservoirs are in fluid communication through one or more conduits. 96. The method according to any one of clauses 81-95, wherein the polymeric structure further comprises a connector configured to couple the polymeric structure to a fluid reservoir. 97. The method according to clause 73, wherein the reservoir further comprises a pump component configured to convey a fluidic medium from the reservoir through the polymeric microneedles. 98. The method according to any one of clauses 81-83, wherein the method comprises applying the polymeric structure to the skin surface of the subject in a manner sufficient to collect a biological fluid sample from the subject into the microneedles. 99. The method according to clause 98, wherein the biological fluid sample comprises interstitial fluid. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 100. The method according to clause 98, wherein the biological fluid sample comprises dermal fluid. 101. The method according to any one of any one of clauses 98-100, wherein the method comprises collecting from 0.01 µL to 250 µL of the biological fluid from the subject. 102. The method according to any one of any one of clauses 98-100, wherein the method comprises collecting from 0.01 µL to 2 µL of the biological fluid from the subject with each of the plurality of microneedles. 103. The method according to any one of clauses 98-102, wherein the method further comprises conveying the collected biological fluid sample through a microfluidic channel in fluidic communication with the polymeric structure. 104. The method according to clause 103, wherein the microfluidic channel is in fluid communication with a reservoir. 105. The method according to clause 104, wherein the reservoir further comprises a pump component configured to draw the biological fluid sample into the reservoir. 106. The method according to any one of clauses 81-105, wherein the method comprises maintaining the polymeric structure on the skin surface of the subject for an extended period of time. 107. The method according to clause 106, wherein the method comprises maintaining the patch on the skin surface of the subject for 6 hours or longer. 108. The method according to clause 106, wherein the method comprises maintaining the patch on the skin surface of the subject for 12 hours or longer. 109. The method according to clause 106, wherein the method comprises maintaining the patch on the skin surface of the subject for 24 hours or longer. 110. The method according to any one of clauses 81-105, wherein the method comprises removing the polymeric structure in 15 minutes or less from the skin surface of the subject. 111. The method according to any one of clauses 81-110, wherein each polymeric microneedle comprises: a tip section; a body section; and a base section. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 112. The method according to clause 111, wherein one or more of the polymeric microneedles comprises a body section having a width that is greater than the width of the base section. 113. The method according to clause 112, wherein the width of the body section is 25% greater or more than the width of the base section. 114. The method according to any one of clauses 112-113, wherein the base section of each polymeric microneedle has a circular cross-section. 115. The method according to any one of clauses 81-114, wherein one or more of the polymeric microneedles is tear-drop shaped. 116. The method according to clause 111, wherein one or more of the polymeric microneedles comprises a base section having a width that varies along a longitudinal axis of the base section. 117. The method according to clause 116, wherein the base section comprises: a first end having a first width; a second end having a second width; and a middle section between the first end and the second end having a third width. 118. The method according to clause 117, wherein the middle section has a width which is less than width of the first end and the width of the second end. 119. The method according to clause 117, wherein the first width, the second width and the third width are different from each other. 120. The method according to any one of clauses 117-119, wherein: the first width is from 25 µm to 500 µm; the second width is from 25 µm to 500 µm; and the third width is from 1 µm to 100 µm. 121. The method according to any one of clauses 81-114, wherein one or more of the polymeric microneedles has an arrowhead shape. 122. The method according to any one of clauses 81-120, wherein one or more of the polymeric microneedles comprises a square pyramidal or conical projection shape. 123. The method according to any one of clauses 81-122, wherein one or more of the polymeric microneedles comprises a lattice microstructure. 124. The method according to clause 123, wherein the lattice microstructure comprises a plurality of struts. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 125. The method according to clause 124, wherein one or more of the polymeric microneedles comprises a gradient in the number of struts such that the density of struts increases across a longitudinal axis of the microneedle. 126. The method according to any one of clauses 124-125, wherein the struts have a thickness of from 25 µm to 150 µm. 127. The method according to any one of clauses 124-126, wherein one or more of the polymeric microneedles comprises a gradient in the thickness of the struts such that the thickness of the struts increases across a longitudinal axis of the microneedle. 128. The method according to clause 127, wherein the thickness of the struts increases from the tip section to the base section of the polymeric microneedle. 129. The method according to any one of clauses 111-128, wherein one or more of the polymeric microneedles further comprises a pillar in contact with the base section of the polymeric microneedle. 130. The method according to clause 129, wherein the pillar comprises a solid structure. 131. The method according to any one of clauses 111-130, wherein each of the tip section, the body section and the base section has the same cross-sectional shape. 132. The method according to any one of clauses 111-130, wherein one or more of the tip section, the body section and the base section has a different cross-sectional shape. 133. The method according to any one of clauses 131-132, wherein one or more of the tip section, the body section and the base section has a rigid cross cross-sectional shape. 134. The method according to clause 133, wherein each of the tip section, the body section and the base section has a rigid cross cross-sectional shape. 135. The method according to clause 133, wherein the body section and the base section have a rigid cross cross-sectional shape. 136. The method according to any one of clauses 131-132, wherein the tip section has a conical cross-sectional shape. 137. The method according to any one of clauses 111-136, wherein one or more of the polymeric microneedles comprises a beveled tip section. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 138. The method according to clause 137, wherein the tip section of the polymeric microneedle comprises a bevel angle of from 3° to 45°. 139. The method according to any one of clauses 81-138, wherein one or more of the polymeric microneedles is positioned at an angle of 5° to 60° with respect to the skin surface of the subject. 140. The method according to any one of clauses 81-139, wherein one or more of the polymeric microneedles comprises a hollow internal space. 141. The method according to clause 140, wherein one or more of the polymeric microneedles comprises: a tip section comprising a solid structure; a body section comprising a hollow structure; and a base section comprising a solid structure. 142. The method according to clause 140, wherein one or more of the polymeric microneedles comprises: a tip section comprising a solid structure; a body section comprising a lattice structure; and a base section comprising a solid structure. 143. The method according to clause 140, wherein one or more of the polymeric microneedles comprises: a tip section comprising a lattice structure; a body section comprising a hollow structure; and a base section comprising a solid structure. 144. The method according to any one of clauses 140-143, wherein one or more of the polymeric microneedles comprises: a solid tip section; and a body section and a base section that comprises one or more microfluidic channels. 145. The method according to clause 144, wherein the body section comprises an outlet for one of more of the microfluidic channels. 146. The method according to any one of clauses 140-145, wherein one or more of the polymeric microneedles comprises: a tip section that comprises a hollow structure; and Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 a body section and a base section that comprises one or more microfluidic channels. 147. The method according to clause 146, wherein the tip section comprises an outlet for one or more of the microfluidic channels. 148. The method according to clause 146, wherein the body section comprises an outlet for one of more of the microfluidic channels. 149. The method according to any one of clauses 81-148, wherein one or more of the polymeric microneedles are fenestrated. 150. The method according to clause 149, wherein one or more of the tip section, the body section and the base section are fenestrated. 151. The method according to clause 150, wherein the tip section is fenestrated. 152. The method according to clause 150, wherein the body section is fenestrated. 153. The method according to any one of clauses 111-152, wherein each polymeric microneedle has a tip section that comprises a length of from 25 µm to 500 µm. 154. The method according to any one of clauses 111-153, wherein the tip section comprises a base width of 50 µm to 300 µm. 155. The method according to any one of clauses 111-154, wherein each polymeric microneedle has a tip width of from 0.1 µm to 10 µm. 156. The method according to any one of clauses 111-154, wherein each polymeric microneedle has a tip diameter of from 0.1 µm to 10 µm. 157. The method according to any one of clauses 111-156, wherein each polymeric microneedle has a body section that comprises a length of from 50 µm to 1000 µm. 158. The method according to clause 157, wherein the body section comprises a width of 50 µm to 300 µm. 159. The method according to any one of clauses 111-158, wherein each polymeric microneedle has a base section that comprises a length of from 25 µm to 500 µm. 160. The method according to clause 159, wherein the base section comprises a base width of 50 µm to 300 µm. 161. The method according to any one of clauses 81-160, wherein each polymeric microneedle has a volume of from 0.01 µL to 2 µL. 162. The method according to any one of clauses 81-161, wherein the polymeric structure is formed from one or more polymerizable materials. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 163. The method according to any one of clauses 81-161, wherein the polymeric structure is formed from two or more different polymerizable materials. 164. The method according to any one of clauses 162-163, wherein each polymerizable material is selected from the group consisting of polycaprolactone, polyglycolic acid, polylactic acid, polylactic-co-glycolic acid, polyethylene glycol, polyethylene glycol dimethacrylate (PEGDMA), thiol-enes, anhydrides, polyacrylic acid, poly methylmethacrylate, trimethylolpropane triacrylate (TMPTA) monomer, polyvinyl alcohol, polyvinylpyrrolidone, vinyl carbonates, vinyl esters, acrylamides, hyaluronic acid, chitosan, collagen, gelatin, carboxymethylcellulose, and blends or copolymers thereof. 165. The method according to any one of clauses 162-164, wherein the polymerizable material comprises carbon nanotubes. 166. The method according to any one of clauses 81-165, wherein one or more of the polymeric microneedles is formed from a biodegradable polymerizable material. 167. The method according to any one of clauses 81-166, wherein the polymeric microneedles are dissolvable in an aqueous medium. 168. A method of making a polymeric structure comprising one or more polymeric microneedles wherein each polymeric microneedle comprises a microstructural component configured to facilitate one or more of: insertion of the polymeric microneedle into a skin surface of a subject; retention of the polymeric microneedle in the skin of the subject; creating a seal when the polymeric microneedle is inserted into the skin of the subject; and delivery of an active agent to a subject through the polymeric microneedle, wherein the method comprises: a) irradiating a polymerizable composition positioned between a build elevator and a build surface to generate a polymerizable composition comprising a first polymerized region of the polymerizable composition in contact with the build elevator and a first non-polymerized region of the polymerizable composition in contact with the build surface; b) displacing the build elevator away from the build surface; c) irradiating the first non-polymerized region of the polymerizable composition to generate a second polymerized region of the polymerizable composition Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 in contact with the first polymerized region and a second non-polymerized region in contact with the build surface; and d) repeating steps a)-c) in a manner sufficient to generate a polymeric structure comprising one or more polymeric microneedles. 169. The method according to clause 168, wherein the polymerizable composition is in contact with the build elevator and the build surface. 170. The method according to clause 169, wherein the method comprises irradiating the polymerizable composition for a duration sufficient to bond the first polymerized region of the polymerizable composition to the build elevator. 171. The method according to any one of clauses 168-170, wherein the build elevator is displaced in predetermined increments of from 0.5 µm to 1.0 µm. 172. The method according to clause 171, wherein the method further comprises adding polymerizable composition to the build surface after each displacement of the build elevator away from the build surface. 173. The method according to any one of clauses 168-172, wherein the polymerizable composition is irradiated through the build surface. 174. The method according to any one of clauses 168-173, wherein the polymerizable composition is irradiated in the presence of a polymerization inhibitor. 175. The method according to any one of clauses 168-174, wherein the polymerizable composition is continuously polymerized while displacing the build elevator away from the build surface. 176. The method according to any one of clauses 174-175, wherein the build surface is permeable to the polymerization inhibitor. 177. The method according to clause 176, wherein the polymerization inhibitor is oxygen. 178. The method according to any one of clauses 168-177, wherein the polymerizable composition is irradiated with light. 179. The method according to clause 178, wherein the polymerizable composition is irradiated with a micro-digital light projection system. 180. The method according to clause 179, wherein the micro-digital light projection system comprises: a light beam generator component; and Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 a light projection monitoring component. 181. The method according to clause 180, wherein the light beam generator component comprises: a light source; a tube lens; and one or more projection lenses. 182. The method according to any one of clauses 179-181, wherein the light projection monitoring component comprises a photodetector. 183. The method according to clause 182, wherein the photodetector comprises a charge-coupled device (CCD). 184. The method according to any one of clauses 168-183, wherein the method comprises repeating steps a)-c) in a manner sufficient to generate a polymeric structure comprising a plurality of polymeric microneedles. 185. The method according to clause 184, wherein the method comprises repeating steps a)-c) in a manner sufficient to generate a polymeric structure comprising an array of polymeric microneedles. 186. The method according to any one of clauses 168-185, wherein each polymeric microneedle comprises: a tip section; a body section; and a base section. 187. The method according to clause 186, wherein one or more of the polymeric microneedles comprises a body section having a width that is greater than the width of the base section. 188. The method according to clause 187, wherein the width of the body section is 25% greater or more than the width of the base section. 189. The method according to any one of clauses 186-188, wherein the base section of each polymeric microneedle has a circular cross-section. 190. The method according to any one of clauses 168-189, wherein one or more of the polymeric microneedles is tear-drop shaped. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 191. The method according to clause 186, wherein one or more of the polymeric microneedles comprises a base section having a width that varies along a longitudinal axis of the base section. 192. The method according to clause 191, wherein the base section comprises: a first end having a first width; a second end having a second width; and a middle section between the first end and the second end having a third width. 193. The method according to clause 192, wherein the middle section has a width which is less than width of the first end and the width of the second end. 194. The method according to clause 193, wherein the first width, the second width and the third width are different from each other. 195. The method according to any one of clauses 192-194, wherein: the first width is from 25 µm to 500 µm; the second width is from 25 µm to 500 µm; and the third width is from 1 µm to 100 µm. 196. The method according to any one of clauses 168-189, wherein one or more of the polymeric microneedles has an arrowhead shape. 197. The method according to any one of clauses 168-196, wherein one or more of the polymeric microneedles comprises a square pyramidal or conical projection shape. 198. The method according to any one of clauses 168-197, wherein one or more of the polymeric microneedles comprises a lattice microstructure. 199. The method according to clause 198, wherein the lattice microstructure comprises a plurality of struts. 200. The method according to clause 199, wherein one or more of the polymeric microneedles comprises a gradient in the number of struts such that the density of struts increases across a longitudinal axis of the microneedle. 201. The method according to any one of clauses 199-200, wherein the struts have a thickness of from 25 µm to 150 µm. 202. The method according to any one of clauses 199-201, wherein one or more of the polymeric microneedles comprises a gradient in the thickness of the struts such that the thickness of the struts increases across a longitudinal axis of the microneedle. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 203. The method according to clause 202, wherein the thickness of the struts increases from the tip section to the base section of the polymeric microneedle. 204. The method according to any one of clauses 186-203, wherein one or more of the polymeric microneedles further comprises a pillar in contact with the base section of the polymeric microneedle. 205. The method according to clause 204, wherein the pillar comprises a solid structure. 206. The method according to any one of clauses 186-205, wherein each of the tip section, the body section and the base section has the same cross-sectional shape. 207. The method according to any one of clauses 186-206, wherein one or more of the tip section, the body section and the base section has a different cross-sectional shape. 208. The method according to any one of clauses 206-207, wherein one or more of the tip section, the body section and the base section has a rigid cross cross-sectional shape. 209. The method according to clause 208, wherein each of the tip section, the body section and the base section has a rigid cross cross-sectional shape. 210. The method according to clause 208, wherein the body section and the base section have a rigid cross cross-sectional shape. 211. The method according to any one of clauses 209-210, wherein the tip section has a conical cross-sectional shape. 212. The method according to any one of clauses 186-211, wherein one or more of the polymeric microneedles comprises a beveled tip section. 213. The method according to clause 212, wherein the tip section of the polymeric microneedle comprises a bevel angle of from 3° to 45°. 214. The method according to any one of clauses 168-213, wherein one or more of the polymeric microneedles is positioned at an angle of 5° to 60° with respect to the skin surface of the subject. 215. The method according to any one of clauses 168-214, wherein one or more of the polymeric microneedles comprises a hollow internal space. 216. The method according to clause 215, wherein one or more of the polymeric microneedles comprises: Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 a tip section comprising a solid structure; a body section comprising a hollow structure; and a base section comprising a solid structure. 217. The method according to clause 215, wherein one or more of the polymeric microneedles comprises: a tip section comprising a solid structure; a body section comprising a lattice structure; and a base section comprising a solid structure. 218. The method according to clause 215, wherein one or more of the polymeric microneedles comprises: a tip section comprising a lattice structure; a body section comprising a hollow structure; and a base section comprising a solid structure. 219. The method according to any one of clauses 215-218, wherein one or more of the polymeric microneedles comprises: a solid tip section; and a body section and a base section that comprises one or more microfluidic channels. 220. The method according to clause 219, wherein the body section comprises an outlet for one of more of the microfluidic channels. 221. The method according to any one of clauses 215-220, wherein one or more of the polymeric microneedles comprises: a tip section that comprises a hollow structure; and a body section and a base section that comprises one or more microfluidic channels. 222. The method according to clause 221, wherein the tip section comprises an outlet for one or more of the microfluidic channels. 223. The method according to clause 221, wherein the body section comprises an outlet for one of more of the microfluidic channels. 224. The method according to any one of clauses 168-223, wherein one or more of the polymeric microneedles are fenestrated. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 225. The method according to clause 224, wherein one or more of the tip section, the body section and the base section are fenestrated. 226. The method according to clause 225, wherein the tip section is fenestrated. 227. The method according to clause 225, wherein the body section is fenestrated. 228. The method according to any one of clauses 186-227, wherein each polymeric microneedle has a tip section that comprises a length of from 25 µm to 500 µm. 229. The method according to any one of clauses 186-228, wherein the tip section comprises a base width of 50 µm to 300 µm. 230. The method according to any one of clauses 186-229, wherein each polymeric microneedle has a tip width of from 0.1 µm to 10 µm. 231. The method according to any one of clauses 186-229, wherein each polymeric microneedle has a tip diameter of from 0.1 µm to 10 µm. 232. The method according to any one of clauses 186-231, wherein each polymeric microneedle has a body section that comprises a length of from 50 µm to 1000 µm. 233. The method according to clause 232, wherein the body section comprises a width of 50 µm to 300 µm. 234. The method according to any one of clauses 186-233, wherein each polymeric microneedle has a base section that comprises a length of from 25 µm to 500 µm. 235. The method according to clause 234, wherein the base section comprises a base width of 50 µm to 300 µm. 236. The method according to any one of clauses 168-235, wherein each polymeric microneedle has a volume of from 0.01 µL to 2 µL. 237. The method according to any one of clauses 168-236, wherein the polymeric structure is formed from one or more polymerizable materials. 238. The method according to any one of clauses 168-236, wherein the polymeric structure is formed from two or more different polymerizable materials. 239. The method according to any one of clauses 237-238, wherein each polymerizable material is selected from the group consisting of polycaprolactone, polyglycolic acid, polylactic acid, polylactic-co-glycolic acid, polyethylene glycol, polyethylene glycol dimethacrylate (PEGDMA), thiol-enes, anhydrides, polyacrylic acid, poly methylmethacrylate, trimethylolpropane triacrylate (TMPTA) monomer, polyvinyl Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 alcohol, polyvinylpyrrolidone, vinyl carbonates, vinyl esters, acrylamides, hyaluronic acid, chitosan, collagen, gelatin, carboxymethylcellulose, and blends or copolymers thereof. 240. The method according to any one of clauses 237-239, wherein the polymerizable material comprises carbon nanotubes. 241. The method according to any one of clauses 168-240, wherein one or more of the polymeric microneedles is formed from a biodegradable polymerizable material. 242. The method according to any one of clauses 168-241, wherein the polymeric microneedles are dissolvable in an aqueous medium. 243. A kit comprising: a polymeric structure according to any one of clauses 1-80 comprising one or more polymeric microneedles, wherein each polymeric microneedle comprises a microstructural component configured to facilitate one or more of: insertion of the polymeric microneedle into a skin surface of a subject; retention of the polymeric microneedle in the skin of the subject; creating a seal when the polymeric microneedle is inserted into the skin of the subject; delivery of an active agent to a subject through the polymeric microneedle; and instructions for applying the polymeric structure to a skin surface of a subject. 244. The kit according to clause 243, wherein the kit comprises two or more of the polymeric structures. 245. The kit according to any one of clauses 243-244, wherein the kit further comprises an active agent compound. 246. The kit according to clause 245, wherein the active agent compound comprises a small molecule active agent compound. 247. The kit according to clause 245, wherein the active agent compound comprises an immunogenic active agent compound. 248. The kit according to clause 247, wherein the active agent compound comprises a vaccine. 249. The kit according to any one of clauses 245-248, wherein the active agent compound is lyophilized. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 250. The kit according to any one of clauses 245-248, wherein one or more of the polymeric microneedles comprises a hydrogel comprising the active agent compound. 251. The kit according to any one of clauses 245-250, wherein the active agent compound is a unreconstituted solid. 252. The kit according to any one of clauses 249-251, wherein the kit comprises instructions for applying the polymeric structure to the skin surface of the subject to collect a biological fluid sample from the subject into the microneedles. 253. The kit according to clause 252, wherein the biological fluid sample comprises interstitial fluid. 254. The kit according to clause 252, wherein the biological fluid sample comprises dermal fluid. 255. The kit according to any one of clauses 243-254, wherein the kit further comprises a backing layer. 256. The kit according to clause 255, wherein the backing layer comprises a pressure sensitive adhesive. 257. The kit according to any one of clauses 243-256, wherein the polymeric structure comprises a plurality of polymeric microneedles. 258. The kit according to clause 257, wherein the polymeric structure comprises an array of polymeric microneedles. 259. The kit according to any one of clauses 243-258, wherein the polymeric structure comprises a plurality of microfluidic channels. 260. The kit according to clause 259, wherein microfluidic channels are in fluid communication with a source of a fluidic medium. 261. The kit according to any one of clauses 259-260, wherein the microfluidic channels are in fluid communication with a reservoir. 262. The kit according to any one of clauses 259-261, wherein the polymeric structure is configured to convey a fluidic medium from the microfluidic channels through the polymeric microneedles. 263. The kit according to any one of clauses 261-262, wherein each polymeric microneedle is in fluid communication with a different reservoir. 264. The kit according to clause 263, wherein the polymeric structure comprises an array of reservoirs. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 265. The kit according to clause 264, wherein the array of reservoirs are in fluid communication through one or more conduits. 266. The kit according to any one of clauses 243-265, wherein the polymeric structure further comprises a connector configured to couple the polymeric structure to a fluid reservoir. 267. The kit according to clause 266, wherein the connector comprises a Luer-lock fitting. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims. Accordingly, the preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the claims. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims. In the claims, 35 U.S.C. §112(f) or 35 U.S.C. §112(6) is expressly defined as being invoked for a limitation in the claim Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 only when the exact phrase "means for" or the exact phrase "step for" is recited at the beginning of such limitation in the claim; if such exact phrase is not used in a limitation in the claim, then 35 U.S.C. § 112 (f) or 35 U.S.C. §112(6) is not invoked.

Claims

Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 What is claimed is: 1. A polymeric structure comprising one or more polymeric microneedles, wherein each polymeric microneedle comprises a microstructural component configured to facilitate one or more of: insertion of the polymeric microneedle into a skin surface of a subject; retention of the polymeric microneedle in the skin of the subject; creating a seal when the polymeric microneedle is inserted into the skin of the subject; and delivery of an active agent to a subject through the polymeric microneedle. 2. The polymeric structure according to claim 1, wherein each polymeric microneedle comprises: a tip section; a body section; and a base section. 3. The polymeric structure according to claim 2, wherein one or more of the polymeric microneedles has a shape selected from tear-drop shaped and arrowhead shape. 4. The polymeric structure according to claim 2, wherein one or more of the tip section, the body section and the base section has a rigid cross cross-sectional shape. 5. The polymeric structure according to claim 4, wherein each of the tip section, the body section and the base section has a rigid cross cross-sectional shape. 6. The polymeric structure according to claim 4, wherein the body section and the base section have a rigid cross cross-sectional shape and the tip section has a conical cross-sectional shape. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 7. The polymeric structure according to any one of claims 1-6, wherein one or more of the polymeric microneedles comprises a beveled tip section. 8. The polymeric structure according to any one of claims 2-7, wherein one or more of the polymeric microneedles comprises: a solid tip section; and a body section and a base section that comprises one or more microfluidic channels. 9. The polymeric structure according to any one of claims 1-8, wherein one or more of the polymeric microneedles are fenestrated. 10. The polymeric structure according to any one of claims 1-9, wherein the polymeric structure comprises one or more microfluidic channels. 11. A method comprising applying to a skin surface of a subject a polymeric structure comprising one or more polymeric microneedles, wherein each polymeric microneedle comprises a microstructural component configured to facilitate one or more of: insertion of the polymeric microneedle into a skin surface of a subject; retention of the polymeric microneedle in the skin of the subject; creating a seal when the polymeric microneedle is inserted into the skin of the subject; and delivery of an active agent to a subject through the polymeric microneedle. 12. The method according to claim 11, wherein the method comprises applying the polymeric structure to the skin surface of the subject in a manner sufficient to deliver an active agent compound to the subject. 13. The method according to claim 11, wherein the method comprises applying the polymeric structure to the skin surface of the subject in a manner sufficient to collect a biological fluid sample from the subject into the microneedles. Attorney Docket No.: STAN-2101WO Stanford No.: S23-158 14. A kit comprising: a polymeric structure according to any one of claims 1-13 comprising one or more polymeric microneedles, wherein each polymeric microneedle comprises a microstructural component configured to facilitate one or more of: insertion of the polymeric microneedle into a skin surface of a subject; retention of the polymeric microneedle in the skin of the subject; creating a seal when the polymeric microneedle is inserted into the skin of the subject; delivery of an active agent to a subject through the polymeric microneedle; and instructions for applying the polymeric structure to a skin surface of a subject. 15. The kit according to claim 14, wherein the kit further comprises one or more of: an active agent compound; a fluid reservoir; and a connector configured to couple the polymeric structure to the fluid reservoir.